{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:25:08Z","timestamp":1787016308173,"version":"build-2736575974"},"reference-count":1286,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1124\/pharmrev.121.000523","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T12:35:18Z","timestamp":1678797318000},"page":"554-674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-8467","authenticated-orcid":false,"given":"Martin C.","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Chermansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Wein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Erik","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.121.000523_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00439-19","article-title":"Potential role of extracellular ATP released by bacteria in bladder infection and contractility","volume":"4","author":"Abbasian","year":"2019","journal-title":"MSphere"},{"key":"10.1124\/pharmrev.121.000523_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13293-018-0204-8","article-title":"Sex differences in lower urinary tract biology and physiology","volume":"9","author":"Abelson","year":"2018","journal-title":"Biol Sex Differ"},{"key":"10.1124\/pharmrev.121.000523_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bju.13759","article-title":"Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"119","author":"Abo Youssef","year":"2017","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","article-title":"Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction","volume":"175","author":"Abrams","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1464-410X.2008.07523.x","article-title":"Clinical relevance of health-related quality of life outcomes with darifenacin","volume":"102","author":"Abrams","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00345-016-1908-1","volume":"35","author":"Abrams","year":"2017","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2005.06.007","article-title":"Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis","volume":"48","author":"Abrams","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.euf.2020.06.013","article-title":"Predictors of poor response and adverse events following botulinum toxin A for refractory idiopathic overactive bladder: a systematic review","volume":"7","author":"Abrar","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1124\/pharmrev.121.000523_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1756287220922425","article-title":"Pharmacology of the lower urinary tract: update on LUTS treatment","volume":"12","author":"Abreu-Mendes","year":"2020","journal-title":"Ther Adv Urol"},{"key":"10.1124\/pharmrev.121.000523_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pathophys.2018.12.003","article-title":"Dietary macronutrients modulate hypertrophy and contractility of the detrusor in an experimental model of bladder obstruction","volume":"26","author":"Adedeji","year":"2019","journal-title":"Pathophysiology"},{"key":"10.1124\/pharmrev.121.000523_bib15","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1038\/s41598-018-22934-1","article-title":"Phosphodiesterase type 4 inhibition enhances nitric oxide- and hydrogen sulfide-mediated bladder neck inhibitory neurotransmission","volume":"8","author":"Agis-Torres","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.121.000523_bib16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/nau.23532","article-title":"KPR-2579, a novel TRPM8 antagonist, inhibits acetic acid-induced bladder afferent hyperactivity in rats","volume":"37","author":"Aizawa","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib17","doi-asserted-by":"crossref","first-page":"173995","DOI":"10.1016\/j.ejphar.2021.173995","article-title":"Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and \u03b23-adrenoceptor agonist or anticholinergic agent on bladder dysfunction in rats with bladder overactivity","volume":"899","author":"Aizawa","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bju.13223","article-title":"URB937, a peripherally restricted inhibitor for fatty acid amide hydrolase, reduces prostaglandin E2 -induced bladder overactivity and hyperactivity of bladder mechano-afferent nerve fibres in rats","volume":"117","author":"Aizawa","year":"2016","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","article-title":"Effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","volume":"62","author":"Aizawa","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.juro.2012.10.060","article-title":"Characteristics of lower urinary tract dysfunction and bladder afferent nerve properties in type 2 diabetic Goto-Kakizaki rats","volume":"189","author":"Aizawa","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/nau.22571","article-title":"Effects of L-arginine, mirabegron, and oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, rhythmic bladder contractions in the rat","volume":"34","author":"Aizawa","year":"2015","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.121.000523_bib22","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.4111\/icu.2017.58.S2.S82","article-title":"Pathophysiology of the underactive bladder","volume":"58","author":"Aizawa","year":"2017","journal-title":"Investig Clin Urol"},{"key":"10.1124\/pharmrev.121.000523_bib23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/nau.20826","article-title":"Effects of CL316,243, a \u03b2 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat","volume":"29","author":"Aizawa","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/nau.22920","article-title":"Inhibitory effects of retigabine, a Kv7 channel activator, on mechanosensitive primary bladder afferent activities and nociceptive behaviors in rats","volume":"36","author":"Aizawa","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/nau.21212","article-title":"Effects of TRPV4 cation channel activation on the primary bladder afferent activities of the rat","volume":"31","author":"Aizawa","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.juro.2014.09.102","article-title":"Pelvic arterial occlusive disease affects the RhoA\/Rho-kinase pathway in bladder smooth muscle","volume":"193","author":"Akaihata","year":"2015","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib27","doi-asserted-by":"crossref","first-page":"238.e7","DOI":"10.1016\/j.urology.2017.10.007","article-title":"Protective effect of a rho-kinase inhibitor on bladder dysfunction in a rat model of chronic bladder ischemia","volume":"111","author":"Akaihata","year":"2018","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/bju.13847","article-title":"cAMP-dependent regulation of RhoA\/Rho-kinase attenuates detrusor overactivity in a novel mouse experimental model","volume":"120","author":"Akakpo","year":"2017","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1464-410X.2007.06977.x","article-title":"Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction","volume":"100","author":"Akbar","year":"2007","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/luts.12058","article-title":"Impact of rho-kinase inhibitor hydroxyfasudil in protamine sulphate induced cystitis rat bladder","volume":"7","author":"Akin","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib31","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1701-2163(16)31015-5","article-title":"What is the available evidence for hormone replacement therapy in women with stress urinary incontinence?","volume":"25","author":"Al-Badr","year":"2003","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1124\/pharmrev.121.000523_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jpedsurg.2018.05.012","article-title":"Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: a preliminary report","volume":"54","author":"Al Edwan","year":"2019","journal-title":"J Pediatr Surg"},{"key":"10.1124\/pharmrev.121.000523_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000365688","article-title":"Efficacy of duloxetine in the early management of urinary continence after radical prostatectomy","volume":"8","author":"Alan","year":"2015","journal-title":"Curr Urol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000523_bib34","first-page":"S27","article-title":"The concise guide to pharmacology 2021\/22: G protein-coupled receptors","volume":"178","author":"Alexander","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000523_bib35","first-page":"S1","article-title":"The concise guide to pharmacology 2019\/20: introduction and other protein targets","volume":"176","author":"Alexander","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bph.13367","article-title":"Mirabegron relaxes urethral smooth muscle by a dual mechanism involving \u03b23-adrenoceptor activation and \u03b11-adrenoceptor blockade","volume":"173","author":"Alexandre","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib37","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/pon.1033","article-title":"Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors","volume":"15","author":"Alfano","year":"2006","journal-title":"Psychooncology"},{"key":"10.1124\/pharmrev.121.000523_bib38","article-title":"Adrenergic drugs for urinary incontinence in adults","volume":"2005","author":"Alhasso","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1464-410X.2009.09129.x","article-title":"Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study","volume":"106","author":"Alloussi","year":"2010","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib40","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/j.1464-410X.2008.08285.x","article-title":"Failure of monotherapy in primary monosymptomatic enuresis: a combined desmopressin and propiverine treatment regimen improves efficacy outcomes","volume":"103","author":"Alloussi","year":"2009","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpurol.2010.04.014","article-title":"Desmopressin treatment regimens in monosymptomatic and nonmonosymptomatic enuresis: a review from a clinical perspective","volume":"7","author":"Alloussi","year":"2011","journal-title":"J Pediatr Urol"},{"key":"10.1124\/pharmrev.121.000523_bib42","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1523\/JNEUROSCI.5606-11.2012","article-title":"Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature","volume":"32","author":"Almeida","year":"2012","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1292\/jvms.18-0631","article-title":"Involvement of transient receptor potential melastatin 4 channels in the resting membrane potential setting and cholinergic contractile responses in mouse detrusor and ileal smooth muscles","volume":"81","author":"Alom","year":"2019","journal-title":"J Vet Med Sci"},{"key":"10.1124\/pharmrev.121.000523_bib44","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0022-5347(05)00400-3","article-title":"Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele","volume":"175","author":"Altaweel","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0974-7796.82170","article-title":"Prospective randomized trial of 100u vs 200u Botox in the treatment of idiopathic overactive bladder","volume":"3","author":"Altaweel","year":"2011","journal-title":"Urol Ann"},{"key":"10.1124\/pharmrev.121.000523_bib46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/nau.22945","article-title":"Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study","volume":"36","author":"Amarenco","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/00365598609024495","article-title":"The effect of noradrenaline on the contractile response of the urinary bladder. An in vitro study in man and cat","volume":"20","author":"Amark","year":"1986","journal-title":"Scand J Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib48","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.eururo.2008.01.007","article-title":"Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects","volume":"53","author":"Amend","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/jcm10020311","article-title":"Factors associated with decisions for initial dosing, up-titration of propiverine and treatment outcomes in overactive bladder syndrome patients in a non-interventional setting","volume":"10","author":"Amiri","year":"2021","journal-title":"J Clin Med"},{"key":"10.1124\/pharmrev.121.000523_bib50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.eururo.2018.02.011","article-title":"Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial","volume":"74","author":"Amundsen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib51","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2016.14617","article-title":"OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial","volume":"316","author":"Amundsen","year":"2016","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.121.000523_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"key":"10.1124\/pharmrev.121.000523_bib53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0031-6997(25)00442-9","article-title":"Pharmacology of lower urinary tract smooth muscles and penile erectile tissues","volume":"45","author":"Anderson","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MOU.0000000000000122","article-title":"Intraprostatic injections for lower urinary tract symptoms treatment","volume":"25","author":"Andersson","year":"2015","journal-title":"Curr Opin Urol"},{"key":"10.1124\/pharmrev.121.000523_bib55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrurol.2017.113","article-title":"Pharmacology: cardiovascular effects of mirabegron","volume":"14","author":"Andersson","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1124\/pharmrev.121.000523_bib56","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/13543784.2019.1654994","article-title":"Agents in early development for treatment of bladder dysfunction\u2014promise of drugs acting at TRP channels?","volume":"28","author":"Andersson","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib57","series-title":"Incontinence","first-page":"805","article-title":"Pharmacological treatement of urinary incontinence","author":"Andersson","year":"2017"},{"issue":"Suppl 4","key":"10.1124\/pharmrev.121.000523_bib58","first-page":"S117","article-title":"Which molecular targets do we need to focus on to improve lower urinary tract dysfunction? ICI-RS 2017","volume":"37","author":"Andersson","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib59","series-title":"Urinary Tract","year":"2011"},{"key":"10.1124\/pharmrev.121.000523_bib60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.121.000523_bib61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1742-1241.2006.01184.x","article-title":"Treatment-resistant detrusor overactivity\u2014underlying pharmacology and potential mechanisms","volume":"151","author":"Andersson","year":"2006","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1124\/pharmrev.121.000523_bib62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","article-title":"Antimuscarinic mechanisms and the overactive detrusor: an update","volume":"59","author":"Andersson","year":"2011","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/pr.111.004515","article-title":"Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction","volume":"63","author":"Andersson","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib64","series-title":"Urinary Tract","first-page":"319","article-title":"Muscarinic acetylcholine receptors in the urinary tract","author":"Andersson","year":"2011"},{"key":"10.1124\/pharmrev.121.000523_bib65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.autneu.2015.04.012","article-title":"Purinergic signalling in the urinary bladder","volume":"191","author":"Andersson","year":"2015","journal-title":"Auton Neurosci"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.121.000523_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bcpt.12577","article-title":"Potential future pharmacological treatment of bladder dysfunction","volume":"119","author":"Andersson","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.121.000523_bib67","first-page":"67","article-title":"TRP channels as lower urinary tract sensory targets","volume":"7","author":"Andersson","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"10.1124\/pharmrev.121.000523_bib68","series-title":"Incontinence","first-page":"447","article-title":"Pharmacological treatment of urinary incontinence","author":"Andersson","year":"1999"},{"key":"10.1124\/pharmrev.121.000523_bib69","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/physrev.00038.2003","article-title":"Urinary bladder contraction and relaxation: physiology and pathophysiology","volume":"84","author":"Andersson","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib70","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MOU.0b013e32832ce8a4","article-title":"Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence","volume":"19","author":"Andersson","year":"2009","journal-title":"Curr Opin Urol"},{"key":"10.1124\/pharmrev.121.000523_bib71","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2147\/TCRM.S291798","article-title":"Gene therapy for overactive bladder: a review of BK-channel \u03b1-subunit gene transfer","volume":"17","author":"Andersson","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/pharmrev.121.000523_bib72","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/nau.20999","article-title":"Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action","volume":"30","author":"Andersson","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib73","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11095-019-2628-1","article-title":"Pharmacokinetic and pharmacodynamic properties of a micro-dose nasal spray formulation of desmopressin (AV002) in healthy water-loaded subjects","volume":"36","author":"Andersson","year":"2019","journal-title":"Pharm Res"},{"key":"10.1124\/pharmrev.121.000523_bib74","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2165\/00003495-200363230-00003","article-title":"CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention","volume":"63","author":"Andersson","year":"2003","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib75","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0306-3623(93)90156-R","article-title":"The L-arginine\/nitric oxide pathway and non-adrenergic, non-cholinergic relaxation of the lower urinary tract","volume":"24","author":"Andersson","year":"1993","journal-title":"Gen Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib76","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/pr.56.4.4","article-title":"Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence","volume":"56","author":"Andersson","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.autneu.2012.06.004","article-title":"Muscarinic receptor subtypes involved in urothelium-derived relaxatory effects in the inflamed rat urinary bladder","volume":"170","author":"Andersson","year":"2012","journal-title":"Auton Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib78","doi-asserted-by":"crossref","first-page":"F1223","DOI":"10.1152\/ajprenal.00535.2010","article-title":"TRPA1 receptor modulation attenuates bladder overactivity induced by spinal cord injury","volume":"300","author":"Andrade","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib79","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1515\/jbcpp-2017-0071","article-title":"Calcium sensitization mechanisms in detrusor smooth muscles","volume":"29","author":"Anjum","year":"2018","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejphar.2017.08.043","article-title":"Enhancement of S1P-induced contractile response in detrusor smooth muscle of rats having cystitis","volume":"814","author":"Anjum","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpurol.2011.10.022","article-title":"Gabapentin: a novel drug as add-on therapy in cases of refractory overactive bladder in children","volume":"9","author":"Ansari","year":"2013","journal-title":"J Pediatr Urol"},{"key":"10.1124\/pharmrev.121.000523_bib82","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MOU.0000000000000064","article-title":"Biomarkers in lower urinary tract symptoms\/overactive bladder: a critical overview","volume":"24","author":"Antunes-Lopes","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1124\/pharmrev.121.000523_bib83","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","article-title":"Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A","volume":"26","author":"Aoki","year":"2005","journal-title":"Neurotoxicology"},{"key":"10.1124\/pharmrev.121.000523_bib84","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1600-0854.2003.00156.x","article-title":"The uroepithelium: not just a passive barrier","volume":"5","author":"Apodaca","year":"2004","journal-title":"Traffic"},{"key":"10.1124\/pharmrev.121.000523_bib85","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.urology.2004.10.007","article-title":"Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin","volume":"65","author":"Apostolidis","year":"2005","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib86","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib87","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.eururo.2006.04.006","article-title":"Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation","volume":"50","author":"Apostolidis","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib88","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.eururo.2008.02.037","article-title":"Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity","volume":"53","author":"Apostolidis","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib89","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib90","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00345-012-0984-0","article-title":"An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity","volume":"31","author":"Apostolidis","year":"2013","journal-title":"World J Urol"},{"issue":"Suppl 4","key":"10.1124\/pharmrev.121.000523_bib91","first-page":"S38","article-title":"Is there \u201cbrain OAB\u201d and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017","volume":"37","author":"Apostolidis","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib92","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/pharmrev.121.000523_bib93","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/nau.23490","article-title":"A systematic review of urinary bladder hypertrophy in experimental diabetes: part I. Streptozotocin-induced rat models","volume":"37","author":"Arioglu Inan","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib94","first-page":"E520","article-title":"The intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity","volume":"14","author":"Asafu-Adjei","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1124\/pharmrev.121.000523_bib95","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1464-410x.1999.00012.x","article-title":"Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study","volume":"83","author":"Asplund","year":"1999","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib96","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/brain\/124.2.369","article-title":"Brain responses to changes in bladder volume and urge to void in healthy men","volume":"124","author":"Athwal","year":"2001","journal-title":"Brain"},{"key":"10.1124\/pharmrev.121.000523_bib97","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1542\/peds.2007-3691","article-title":"Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial","volume":"122","author":"Austin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1124\/pharmrev.121.000523_bib98","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/nau.24588","article-title":"OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children","volume":"40","author":"Austin","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib99","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/nau.23052","article-title":"Less is more\u2014a pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity","volume":"36","author":"Avallone","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.juro.2007.03.096","article-title":"Oxidative stress and neurodegeneration in the ischemic overactive bladder","volume":"178","author":"Azadzoi","year":"2007","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib101","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"key":"10.1124\/pharmrev.121.000523_bib102","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.juro.2007.03.042","article-title":"The effects of long-term administration of oral desmopressin on the baseline secretion of antidiuretic hormone and serum sodium concentration for the treatment of nocturia: a circadian study","volume":"178","author":"Bae","year":"2007","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib103","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3346\/jkms.2015.30.9.1313","article-title":"Effects of moderate alcohol intake in the bladder of the Otsuka Long Evans Tokushima fatty diabetic rats","volume":"30","author":"Bae","year":"2015","journal-title":"J Korean Med Sci"},{"key":"10.1124\/pharmrev.121.000523_bib104","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/nau.24657","article-title":"Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: an open-label, phase 3, dose-titration study","volume":"40","author":"Baka-Ostrowska","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib105","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00210-014-0973-5","article-title":"Human urothelial cell lines as potential models for studying cannabinoid and excitatory receptor interactions in the urinary bladder","volume":"387","author":"Bakali","year":"2014","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib106","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00192-016-2984-x","article-title":"Effects of cannabinoid receptor activation by CP55,940 on normal bladder function and irritation-induced bladder overactivity in non-awake anaesthetised rats","volume":"27","author":"Bakali","year":"2016","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib107","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00192-014-2360-7","article-title":"Women\u2019s perspective: intra-detrusor Botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment","volume":"25","author":"Balchandra","year":"2014","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib108","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7326\/M18-3227","article-title":"Pharmacologic and nonpharmacologic treatments for urinary incontinence in women: a systematic review and network meta-analysis of clinical outcomes","volume":"170","author":"Balk","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1124\/pharmrev.121.000523_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220788","article-title":"Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder","volume":"14","author":"Balog","year":"2019","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejogrb.2018.05.002","article-title":"OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome","volume":"225","author":"Balzarro","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1124\/pharmrev.121.000523_bib111","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ner.12534","article-title":"Neurotransmitter mechanisms underlying sacral neuromodulation of bladder overactivity in cats","volume":"20","author":"Bandari","year":"2017","journal-title":"Neuromodulation"},{"key":"10.1124\/pharmrev.121.000523_bib112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1474-8673.2006.00393.x","article-title":"Effect of short-term outlet obstruction on rat bladder nerve density and contractility","volume":"27","author":"Barendrecht","year":"2007","journal-title":"Auton Autacoid Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib113","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/nau.20642","article-title":"The effect of bladder outlet obstruction on \u03b11- and \u03b2-adrenoceptor expression and function","volume":"28","author":"Barendrecht","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib114","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1464-410X.2006.06742.x","article-title":"Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?","volume":"99","author":"Barendrecht","year":"2007","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib115","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/nau.24326","article-title":"Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder","volume":"39","author":"Baron","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib116","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.juro.2018.10.012","article-title":"Long-term discontinuation of botulinum toxin A intradetrusor injections for neurogenic detrusor overactivity: a multicenter study","volume":"201","author":"Baron","year":"2019","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib117","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib118","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/pds.5098","article-title":"Alzheimer\u2019s disease and related dementias risk: comparing users of non-selective and M3-selective bladder antimuscarinic drugs","volume":"29","author":"Barthold","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1124\/pharmrev.121.000523_bib119","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1464-410X.2008.07769.x","article-title":"A review of adherence to drug therapy in patients with overactive bladder","volume":"102","author":"Basra","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40673-020-00119-9","article-title":"Cerebellum and micturition: what do we know? A systematic review","volume":"7","author":"Bastide","year":"2020","journal-title":"Cerebellum Ataxias"},{"key":"10.1124\/pharmrev.121.000523_bib121","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756287215589250","article-title":"The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial","volume":"7","author":"Batista","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1124\/pharmrev.121.000523_bib122","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0022-5347(05)68247-X","article-title":"A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders","volume":"162","author":"Bayliss","year":"1999","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib123","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5152\/tud.2019.37659","article-title":"Underactive bladder: a review of the current treatment concepts","volume":"45","author":"Bayrak","year":"2019","journal-title":"Turk J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib124","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/nau.23240","article-title":"Efficacy of onabotulinum toxin A injection in pediatric patients with non-neurogenic detrusor overactivity","volume":"36","author":"Bayrak","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00210-014-1060-7","article-title":"Does hypercholesterolemia affect the relaxation of the detrusor smooth muscle in rats? In vitro and in vivo studies","volume":"388","author":"Bayrak","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib126","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","article-title":"Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms","volume":"75","author":"Beavo","year":"1995","journal-title":"Physiol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib127","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-642-16499-6_6","article-title":"Neuroanatomy of the lower urinary tract","volume":"202","author":"Beckel","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.eururo.2010.10.037","article-title":"Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats","volume":"59","author":"Behr-Roussel","year":"2011","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib129","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.juro.2009.02.018","article-title":"Bother related to bladder control and health care seeking behavior in adults in the United States","volume":"181","author":"Benner","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib130","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib131","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7326\/0003-4819-138-6-200303180-00010","article-title":"The relative safety of ephedra compared with other herbal products","volume":"138","author":"Bent","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1124\/pharmrev.121.000523_bib132","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1113\/jphysiol.2008.160440","article-title":"Smooth muscle cell calcium activation mechanisms","volume":"586","author":"Berridge","year":"2008","journal-title":"J Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib133","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2042018810390259","article-title":"\u03b23 receptors: role in cardiometabolic disorders","volume":"2","author":"Bhadada","year":"2011","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1124\/pharmrev.121.000523_bib134","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00192-020-04230-7","article-title":"A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection","volume":"31","author":"Bickhaus","year":"2020","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib135","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1464-410X.2006.06564.x","article-title":"The effects of a new selective \u03b23-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder","volume":"98","author":"Biers","year":"2006","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib136","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1056\/NEJM197701272960407","article-title":"Cardiac antiarrhythmic effect of imipramine hydrochloride","volume":"296","author":"Bigger","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000523_bib137","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1152\/physrev.00030.2012","article-title":"Urothelial signaling","volume":"93","author":"Birder","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib138","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.autneu.2009.07.005","article-title":"Urothelial signaling","volume":"153","author":"Birder","year":"2010","journal-title":"Auton Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib139","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/nn902","article-title":"Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1","volume":"5","author":"Birder","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157424","article-title":"Impaired excitatory neurotransmission in the urinary bladder from the obese Zucker rat: role of cannabinoid receptors","volume":"11","author":"Blaha","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib141","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","article-title":"Prospective pilot study of mirabegron in pediatric patients with overactive bladder","volume":"70","author":"Blais","year":"2016","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib142","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/brain\/121.11.2033","article-title":"Brain activation during micturition in women","volume":"121","author":"Blok","year":"1998","journal-title":"Brain"},{"key":"10.1124\/pharmrev.121.000523_bib143","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1464-410X.2004.04577.x","article-title":"Pharmacological characteristics of Ro 115-1240, a selective \u03b11A\/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence","volume":"93","author":"Blue","year":"2004","journal-title":"BJU Int"},{"issue":"4, Suppl","key":"10.1124\/pharmrev.121.000523_bib144","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.juro.2009.05.099","article-title":"Double anticholinergic therapy for refractory overactive bladder","volume":"182","author":"Bolduc","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib145","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/17425255.2016.1218847","article-title":"Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause","volume":"12","author":"Bondi","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/pharmrev.121.000523_bib146","doi-asserted-by":"crossref","first-page":"C542","DOI":"10.1152\/ajpcell.00033.2014","article-title":"Mechanical stretch upregulates proteins involved in Ca2+ sensitization in urinary bladder smooth muscle hypertrophy","volume":"307","author":"Boopathi","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib147","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0165-6147(99)01413-3","article-title":"The \u201cABC\u201d of GABA receptors","volume":"21","author":"Bormann","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000523_bib148","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.juro.2010.04.011","article-title":"The prevalence and causes of nocturia","volume":"184","author":"Bosch","year":"2010","journal-title":"J Urol"},{"issue":"Suppl 5","key":"10.1124\/pharmrev.121.000523_bib149","first-page":"S56","article-title":"Do functional changes occur in the bladder due to bladder outlet obstruction? ICI-RS 2018","volume":"38","author":"Bosch","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/nau.23291","article-title":"Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed","volume":"37","author":"Bottet","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib151","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1464-410X.2003.04722.x","article-title":"Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment","volume":"93","author":"Brady","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib152","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458504ms1063oa","article-title":"An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis","volume":"10","author":"Brady","year":"2004","journal-title":"Mult Scler"},{"key":"10.1124\/pharmrev.121.000523_bib153","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.105.094961","article-title":"M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder","volume":"316","author":"Braverman","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib154","first-page":"R517","article-title":"Prejunctional M1 facilitory and M2 inhibitory muscarinic receptors mediate rat bladder contractility","volume":"274","author":"Braverman","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib155","first-page":"R1654","article-title":"M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder","volume":"275","author":"Braverman","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib156","doi-asserted-by":"crossref","first-page":"R701","DOI":"10.1152\/ajpregu.00009.2003","article-title":"Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2","volume":"285","author":"Braverman","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib157","doi-asserted-by":"crossref","first-page":"R663","DOI":"10.1152\/ajpregu.00116.2002","article-title":"Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction","volume":"283","author":"Braverman","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib158","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0031-6997(24)01425-X","article-title":"Adrenergic and muscarinic receptors in the human heart","volume":"51","author":"Brodde","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib159","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jpain.2017.01.009","article-title":"Safety, pharmacokinetics, and pharmacodynamics study in healthy subjects of oral NEO6860, a modality selective transient receptor potential vanilloid subtype 1 antagonist","volume":"18","author":"Brown","year":"2017","journal-title":"J Pain"},{"key":"10.1124\/pharmrev.121.000523_bib160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib161","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity","volume":"35","author":"Brynne","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000523_bib162","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.lfs.2007.01.053","article-title":"Expression and distribution of cholinergic receptors in the human urothelium","volume":"80","author":"Bschleipfer","year":"2007","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000523_bib163","first-page":"76","article-title":"Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response","volume":"102","author":"Bump","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib164","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1464-410X.2008.07577.x","article-title":"Long-term efficacy of duloxetine in women with stress urinary incontinence","volume":"102","author":"Bump","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib165","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0022-5347(01)62521-7","article-title":"In situ anatomical study of the male urethral sphincteric complex: relevance to continence preservation following major pelvic surgery","volume":"160","author":"Burnett","year":"1998","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib166","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apha.12012","article-title":"Purinergic signalling in the lower urinary tract","volume":"207","author":"Burnstock","year":"2013","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1124\/pharmrev.121.000523_bib167","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11302-013-9395-y","article-title":"Purinergic signalling in the urinary tract in health and disease","volume":"10","author":"Burnstock","year":"2014","journal-title":"Purinergic Signal"},{"key":"10.1124\/pharmrev.121.000523_bib168","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib169","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/nau.1930120210","article-title":"Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen","volume":"12","author":"Bushman","year":"1993","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib170","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2174\/1381612053764805","article-title":"The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression","volume":"11","author":"Bymaster","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1124\/pharmrev.121.000523_bib171","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neuroscience.2017.03.049","article-title":"Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection","volume":"352","author":"Cai","year":"2017","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000523_bib172","article-title":"Tricyclic and related drugs for nocturnal enuresis in children","volume":"2016","author":"Caldwell","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib173","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","article-title":"A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder","volume":"72","author":"Callegari","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib174","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pros.22930","article-title":"The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?","volume":"75","author":"Calmasini","year":"2015","journal-title":"Prostate"},{"key":"10.1124\/pharmrev.121.000523_bib175","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.juro.2009.05.038","article-title":"Combination drug therapy improves compliance of the neurogenic bladder","volume":"182","author":"Cameron","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib176","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1464-410x.1999.00125.x","article-title":"Desmopressin in the treatment of nocturnal polyuria in the male","volume":"84","author":"Cannon","year":"1999","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib177","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3810\/pgm.2011.01.2250","article-title":"Efficacy and tolerability of solifenacin in patients aged \u2265 65 years with overactive bladder: post-hoc analysis of 2 open-label studies","volume":"123","author":"Cap\u00f3","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1124\/pharmrev.121.000523_bib178","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00404-011-1955-1","article-title":"Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women","volume":"285","author":"Capobianco","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"10.1124\/pharmrev.121.000523_bib179","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00404-013-3030-6","article-title":"Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women","volume":"289","author":"Capobianco","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"10.1124\/pharmrev.121.000523_bib180","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/01.WNF.0000228174.08885.AB","article-title":"Gabapentin treatment of neurogenic overactive bladder","volume":"29","author":"Carbone","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib181","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.11654.x","article-title":"Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)","volume":"111","author":"Cardozo","year":"2013","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib182","first-page":"722","article-title":"Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee","volume":"92","author":"Cardozo","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib183","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/01.AOG.0000134525.86480.0f","article-title":"Pharmacological treatment of women awaiting surgery for stress urinary incontinence","volume":"104","author":"Cardozo","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib184","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1464-410X.2008.07939.x","article-title":"Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial","volume":"102","author":"Cardozo","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib185","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib186","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.0001-6349.2004.00581.x","article-title":"A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder","volume":"83","author":"Cardozo","year":"2004","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1124\/pharmrev.121.000523_bib187","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0378-5122(93)90028-G","article-title":"Oestriol in the treatment of postmenopausal urgency: a multicentre study","volume":"18","author":"Cardozo","year":"1993","journal-title":"Maturitas"},{"key":"10.1124\/pharmrev.121.000523_bib188","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.eururo.2010.07.026","article-title":"Nitric oxide\/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat","volume":"58","author":"Caremel","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib189","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1464-410X.2010.09508.x","article-title":"Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence","volume":"107","author":"Cartwright","year":"2011","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/15.5.299","article-title":"Double-blind study of imipramine and placebo for incontinence due to bladder instability","volume":"15","author":"Castleden","year":"1986","journal-title":"Age Ageing"},{"key":"10.1124\/pharmrev.121.000523_bib191","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/pr.55.4.8","article-title":"International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels","volume":"55","author":"Catterall","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib192","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","article-title":"International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib193","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrurol.2014.53","article-title":"Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS","volume":"11","author":"Cellek","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1124\/pharmrev.121.000523_bib194","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00210-015-1128-z","article-title":"\u03b23-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase","volume":"388","author":"Cernecka","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib195","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00210-012-0767-6","article-title":"Specificity evaluation of antibodies against human \u03b23-adrenoceptors","volume":"385","author":"Cernecka","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib196","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/mol.114.092817","article-title":"The odd sibling: features of \u03b23-adrenoceptor pharmacology","volume":"86","author":"Cernecka","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib197","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0022-5347(01)63020-9","article-title":"The incidence of a positive ice water test in bladder outlet obstructed patients: evidence for bladder neural plasticity","volume":"160","author":"Chai","year":"1998","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib198","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/bph.14669","article-title":"Influence of sildenafil on the purinergic components of nerve-mediated and urothelial ATP release from the bladder of normal and spinal cord injured mice","volume":"176","author":"Chakrabarty","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib199","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.ijo.0801039","article-title":"The tissue distribution of the human \u03b23-adrenoceptor studied using a monoclonal antibody: direct evidence of the \u03b23-adrenoceptor in human adipose tissue, atrium and skeletal muscle","volume":"23","author":"Chamberlain","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pharmrev.121.000523_bib200","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0149-2918(01)80024-2","article-title":"A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate","volume":"23","author":"Chancellor","year":"2001","journal-title":"Clin Ther"},{"key":"10.1124\/pharmrev.121.000523_bib201","first-page":"191","article-title":"Beneficial effect of intranasal desmopressin for men with benign prostatic hyperplasia and nocturia: preliminary results","volume":"5","author":"Chancellor","year":"1999","journal-title":"Tech Urol"},{"key":"10.1124\/pharmrev.121.000523_bib202","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1212\/WNL.0b013e3182a2ca4d","article-title":"OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity","volume":"81","author":"Chancellor","year":"2013","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.121.000523_bib203","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11597530-000000000-00000","article-title":"Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder","volume":"29","author":"Chancellor","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1124\/pharmrev.121.000523_bib204","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11255-016-1277-0","article-title":"Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study","volume":"48","author":"Chancellor","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"Pt B","key":"10.1124\/pharmrev.121.000523_bib205","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.expneurol.2016.05.026","article-title":"A ventral root avulsion injury model for neurogenic underactive bladder studies","volume":"285","author":"Chang","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1124\/pharmrev.121.000523_bib206","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.urology.2005.09.037","article-title":"Multifactorial nature of male nocturia","volume":"67","author":"Chang","year":"2006","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib207","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1185\/03007X226294","article-title":"Darifenacin treatment of patients > or = 65 years with overactive bladder: results of a randomized, controlled, 12-week trial","volume":"23","author":"Chapple","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pharmrev.121.000523_bib208","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","article-title":"Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with \u03b1-blockers","volume":"56","author":"Chapple","year":"2009","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib209","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.02.024","article-title":"The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib210","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bju.12678","article-title":"Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial","volume":"114","author":"Chapple","year":"2014","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib211","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1464-410X.2005.05454.x","article-title":"A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib212","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","article-title":"Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib213","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.juro.2013.08.082","article-title":"Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome","volume":"191","author":"Chapple","year":"2014","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib214","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","article-title":"Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib216","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving nirabegron, antimuscarinics, or placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib217","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib218","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib219","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib220","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2019.09.020","article-title":"Multicriteria decision analysis applied to the clinical use of pharmacotherapy for overactive bladder symptom complex","volume":"6","author":"Chapple","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1124\/pharmrev.121.000523_bib221","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","article-title":"Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe","volume":"59","author":"Chapple","year":"2011","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib222","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2017.01.037","article-title":"Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice","volume":"72","author":"Chapple","year":"2017","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib223","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.eururo.2015.02.030","article-title":"The underactive bladder: a new clinical concept?","volume":"68","author":"Chapple","year":"2015","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib224","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2006.01.037","article-title":"Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL\/0004)","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib226","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib227","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bju.12861","article-title":"Co-administration of TRPV4 and TRPV1 antagonists potentiate the effect of each drug in a rat model of cystitis","volume":"115","author":"Charrua","year":"2015","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib228","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00210-019-01729-9","article-title":"Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide\/palmitoylethanolamine ratio in the inflamed bladder of rats","volume":"393","author":"Charrua","year":"2020","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib229","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.urology.2016.11.008","article-title":"Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial","volume":"100","author":"Chen","year":"2017","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib230","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/10790268.2020.1712892","article-title":"A single-blind randomized control trial of trigonal versus nontrigonal Botulinum toxin-A injections for patients with urinary incontinence and poor bladder compliance secondary to spinal cord injury","volume":"44","author":"Chen","year":"2021","journal-title":"J Spinal Cord Med"},{"key":"10.1124\/pharmrev.121.000523_bib231","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/luts.12156","article-title":"Metabolic syndrome induced bladder cannabinoid receptor changes in the fructose-fed rats","volume":"10","author":"Chen","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib232","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/luts.12262","article-title":"Pathophysiology of refractory overactive bladder","volume":"11","author":"Chen","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib233","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jfma.2018.02.002","article-title":"Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury","volume":"118","author":"Chen","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1124\/pharmrev.121.000523_bib234","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00192-005-1307-4","article-title":"Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC)","volume":"16","author":"Chen","year":"2005","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib235","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fncel.2015.00206","article-title":"Inhibitory effects of endomorphin-2 on excitatory synaptic transmission and the neuronal excitability of sacral parasympathetic preganglionic neurons in young rats","volume":"9","author":"Chen","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib236","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.clnu.2020.09.036","article-title":"Beneficial relevance of vitamin D concentration and urine flow rate","volume":"40","author":"Cheng","year":"2021","journal-title":"Clin Nutr"},{"key":"10.1124\/pharmrev.121.000523_bib237","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2680.2001.00231.x","article-title":"The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro","volume":"21","author":"Chess-Williams","year":"2001","journal-title":"J Auton Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib238","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5213\/inj.2040076.038","article-title":"Management of urinary incontinence with underactive bladder: a review","volume":"24","author":"Cho","year":"2020","journal-title":"Int Neurourol J"},{"key":"10.1124\/pharmrev.121.000523_bib239","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12894-020-00611-8","article-title":"The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction","volume":"20","author":"Choi","year":"2020","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib240","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0022-5347(05)68873-8","article-title":"\u03b1 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia","volume":"161","author":"Chon","year":"1999","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib241","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1464-410X.2006.06058.x","article-title":"Effects of streptozotocin-induced diabetes on bladder and erectile (dys)function in the same rat in vivo","volume":"97","author":"Christ","year":"2006","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib242","doi-asserted-by":"crossref","first-page":"F859","DOI":"10.1152\/ajprenal.00065.2021","article-title":"CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder","volume":"320","author":"Christie","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib243","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/luts.12152","article-title":"Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment","volume":"10","author":"Chua","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib244","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.juro.2017.02.021","article-title":"A prospective,multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis\/bladder pain syndrome","volume":"198","author":"Chuang","year":"2017","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib245","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2009.03.083","article-title":"Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes","volume":"182","author":"Chuang","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib246","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2053369116633017","article-title":"The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women","volume":"22","author":"Chughtai","year":"2016","journal-title":"Post Reprod Health"},{"key":"10.1124\/pharmrev.121.000523_bib247","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/ndt\/gfp472","article-title":"Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats","volume":"25","author":"Chung","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/pharmrev.121.000523_bib248","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1073\/pnas.0931347100","article-title":"Involvement of \u03b2 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function","volume":"100","author":"Cirino","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.121.000523_bib249","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002512-200118040-00005","article-title":"Tolterodine: a review of its use in the treatment of overactive bladder","volume":"18","author":"Clemett","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1124\/pharmrev.121.000523_bib250","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/35039519","article-title":"Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice","volume":"407","author":"Cockayne","year":"2000","journal-title":"Nature"},{"key":"10.1124\/pharmrev.121.000523_bib251","article-title":"Oestrogen therapy for urinary incontinence in post-menopausal women","volume":"10","author":"Cody","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib252","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/nau.23224","article-title":"Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: an immunohistochemical study","volume":"36","author":"Coelho","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib253","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/luts.12273","article-title":"Underactive bladder in aging rats is associated with a reduced number of serotonin-expressing cells in the urethra and is improved by serotonin application to the urethra","volume":"11","author":"Coelho","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib254","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.juro.2011.10.130","article-title":"Effect of onabotulinumtoxinA on intramural parasympathetic ganglia: an experimental study in the guinea pig bladder","volume":"187","author":"Coelho","year":"2012","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib255","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.eururo.2012.01.046","article-title":"Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action","volume":"61","author":"Coelho","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib256","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eururo.2009.12.022","article-title":"Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder","volume":"57","author":"Coelho","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib257","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/nau.20611","article-title":"Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units","volume":"28","author":"Cohen","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib258","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/bju.14236","article-title":"Current concepts of the acontractile bladder","volume":"122","author":"Colaco","year":"2018","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib259","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0022-5347(17)60943-1","article-title":"Favorable experiences with imipramine in the treatment of neurogenic bladder","volume":"107","author":"Cole","year":"1972","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.urology.2011.03.006","article-title":"Postprostatectomy established stress urinary incontinence treated with duloxetine","volume":"78","author":"Collado Serra","year":"2011","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib261","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2006.01.025","article-title":"Histologic features in the urinary bladder wall affected from neurogenic overactivity\u2014a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A","volume":"50","author":"Comp\u00e9rat","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib262","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/jpet.109.154963","article-title":"Pharmacological properties of 2-((R-5-chloro-4-methoxymethylindan-1-yl)-1H-imidazole (PF-3774076), a novel and selective alpha1A-adrenergic partial agonist, in in vitro and in vivo models of urethral function","volume":"330","author":"Conlon","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib263","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/15246090152636541","article-title":"Estrogen, progesterone, and androgen receptor expression in levator ani muscle and fascia","volume":"10","author":"Copas","year":"2001","journal-title":"J Womens Health Gend Based Med"},{"key":"10.1124\/pharmrev.121.000523_bib264","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1464-410X.2005.06031.x","article-title":"A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth","volume":"97","author":"Corcos","year":"2006","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib265","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.eururo.2012.07.004","article-title":"A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management\u2014a systematic review and meta-analysis","volume":"62","author":"Cornu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib266","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2202-4-3","article-title":"Mapping of neurokinin-like immunoreactivity in the human brainstem","volume":"4","author":"Cove\u00f1as","year":"2003","journal-title":"BMC Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib267","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bph.12612","article-title":"Challenges for opioid receptor nomenclature: IUPHAR Review 9","volume":"172","author":"Cox","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib268","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1464-410X.1982.tb13502.x","article-title":"The action of imipramine on the lower urinary tract of the dog","volume":"54","author":"Creed","year":"1982","journal-title":"Br J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib269","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1210\/jc.2004-1496","article-title":"Human bladder as a novel target for vitamin D receptor ligands","volume":"90","author":"Crescioli","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.121.000523_bib270","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib271","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(05)63330-2","article-title":"Suppression of bladder hyperreflexia by intravesical resiniferatoxin","volume":"350","author":"Cruz","year":"1997","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.121.000523_bib272","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0022-5347(01)65211-X","article-title":"Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction","volume":"157","author":"Cruz","year":"1997","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib273","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.121.000523_bib274","first-page":"S26","article-title":"Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB)","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib275","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11255-013-0509-9","article-title":"The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials","volume":"46","author":"Cui","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib276","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF02244985","article-title":"Binding of antidepressants to human brain receptors: focus on newer generation compounds","volume":"114","author":"Cusack","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000523_bib277","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003495-200565010-00008","article-title":"Desmopressin: in adults with nocturia","volume":"65","author":"Cvetkovi\u0107","year":"2005","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib278","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0022-3565(24)37044-2","article-title":"M4 muscarinic autoreceptor-mediated inhibition of -3H-acetylcholine release in the rat isolated urinary bladder","volume":"283","author":"D\u2019Agostino","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib279","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2015.03.074","article-title":"Involvement of \u03b23-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor","volume":"758","author":"D\u2019Agostino","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib280","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/nau.23897","article-title":"The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction","volume":"38","author":"D\u2019Ancona","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"Pt A","key":"10.1124\/pharmrev.121.000523_bib281","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2015.07.333","article-title":"Use of botulinum toxin for genitourinary conditions: What is the evidence?","volume":"107","author":"da Silva","year":"2015","journal-title":"Toxicon"},{"key":"10.1124\/pharmrev.121.000523_bib282","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2016.09.032","article-title":"Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"71","author":"Dahm","year":"2017","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib283","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coph.2014.03.003","article-title":"The pharmacological rationale for combining muscarinic receptor antagonists and \u03b2-adrenoceptor agonists in the treatment of airway and bladder disease","volume":"16","author":"Dale","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib284","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1152\/physrev.00041.2019","article-title":"The urothelium: life in a liquid environment","volume":"100","author":"Dalghi","year":"2020","journal-title":"Physiol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.22543\/7674.71.P2328","article-title":"Underactive bladder\u2014an underestimated entity","volume":"7","author":"Dan","year":"2020","journal-title":"J Mind Med Sci"},{"issue":"6, Suppl","key":"10.1124\/pharmrev.121.000523_bib286","first-page":"S8","article-title":"Animal models of diabetic uropathy","volume":"182","author":"Daneshgari","year":"2009","journal-title":"J Urol"},{"issue":"6, Suppl","key":"10.1124\/pharmrev.121.000523_bib287","first-page":"S18","article-title":"Diabetic bladder dysfunction: current translational knowledge","volume":"182","author":"Daneshgari","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib288","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/10790268.1996.11719431","article-title":"Intravesical capsaicin in neurologic impaired patients with detrusor hyperreflexia","volume":"19","author":"Das","year":"1996","journal-title":"J Spinal Cord Med"},{"key":"10.1124\/pharmrev.121.000523_bib289","series-title":"ICS 2005, 2005 August 28\u2013September 2, Montreal","article-title":"A pilot study to investigate the use of tamsulosin in women with lower urinary tract symptoms","author":"Das","year":"2005"},{"key":"10.1124\/pharmrev.121.000523_bib290","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","article-title":"A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence","volume":"166","author":"Davila","year":"2001","journal-title":"J Urol"},{"issue":"6A, Suppl","key":"10.1124\/pharmrev.121.000523_bib291","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-4295(97)00587-6","article-title":"A neurologic basis for the overactive bladder","volume":"50","author":"de Groat","year":"1997","journal-title":"Urology"},{"issue":"6, Suppl 1","key":"10.1124\/pharmrev.121.000523_bib292","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urology.2004.08.063","article-title":"The urothelium in overactive bladder: passive bystander or active participant?","volume":"64","author":"de Groat","year":"2004","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib293","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1146\/annurev.pharmtox.41.1.691","article-title":"Pharmacology of the lower urinary tract","volume":"41","author":"de Groat","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.121.000523_bib294","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/nau.20761","article-title":"Changes in afferent activity after spinal cord injury","volume":"29","author":"de Groat","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/B978-0-444-63247-0.00005-5","article-title":"Anatomy and physiology of the lower urinary tract","volume":"130","author":"de Groat","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"10.1124\/pharmrev.121.000523_bib296","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.juro.2011.02.039","article-title":"Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction","volume":"185","author":"De Guchtenaere","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib297","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/sj.ijo.0802148","article-title":"Immunohistochemical identification of the \u03b2(3)-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine","volume":"26","author":"De Matteis","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1124\/pharmrev.121.000523_bib298","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0091270010365547","article-title":"Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine","volume":"51","author":"de Mey","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib299","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.eururo.2020.12.032","article-title":"Beyond antimuscarinics: a review of pharmacological and interventional options for overactive bladder management in men","volume":"79","author":"De Nunzio","year":"2021","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib300","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"de Paiva","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.121.000523_bib301","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0022-5347(01)68162-X","article-title":"Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup","volume":"158","author":"De Ridder","year":"1997","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib302","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/nau.23884","article-title":"A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder","volume":"38","author":"de S\u00e1 Dantas Bezerra","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib303","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<513::AID-NAU7>3.0.CO;2-G","article-title":"Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions","volume":"17","author":"de S\u00e8ze","year":"1998","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib304","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/nau.21135","article-title":"Afferent signaling from the bladder: species differences evident from extracellular recordings of pelvic and hypogastric nerves","volume":"30","author":"De Wachter","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib305","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.pain.2014.03.023","article-title":"TRPA1 mediates bladder hyperalgesia in a mouse model of cystitis","volume":"155","author":"DeBerry","year":"2014","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000523_bib306","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000019706","article-title":"Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia","volume":"34","author":"Debruyne","year":"1998","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib307","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/10790268.2017.1314878","article-title":"An investigation of the relationship between autonomic dysreflexia and intrathecal baclofen in patients with spinal cord injury","volume":"41","author":"Del Fabro","year":"2018","journal-title":"J Spinal Cord Med"},{"key":"10.1124\/pharmrev.121.000523_bib308","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2007.09.034","article-title":"Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre","volume":"53","author":"Del Popolo","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib309","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.juro.2008.01.098","article-title":"Stress urinary incontinence: relative importance of urethral support and urethral closure pressure","volume":"179","author":"DeLancey","year":"2008","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib310","first-page":"1559","article-title":"Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients","volume":"19","author":"Dell\u2019Atti","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000523_bib311","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/bcpt.13045","article-title":"Rho kinase and protein kinase C pathways are responsible for enhanced carbachol contraction in permeabilized detrusor in a rat model of cystitis","volume":"123","author":"Denizalti","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.121.000523_bib312","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/nau.22954","article-title":"Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units Dysport\u00ae (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study","volume":"36","author":"Denys","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib313","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/bju.13795","article-title":"Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity","volume":"119","author":"Denys","year":"2017","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib314","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib315","doi-asserted-by":"crossref","first-page":"F1154","DOI":"10.1152\/ajprenal.00106.2019","article-title":"NK2 receptor-mediated detrusor muscle contraction involves Gq\/11-dependent activation of voltage-dependent Ca2+ channels and the RhoA-Rho kinase pathway","volume":"317","author":"D\u00e9r","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib316","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.urology.2019.09.030","article-title":"Safety of intradetrusor onabotulinumtoxinA (BTX-A) injection in the asymptomatic patient with a positive urine dip","volume":"135","author":"Derisavifard","year":"2020","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib317","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.autneu.2016.05.008","article-title":"The use of imaging techniques in understanding lower urinary tract (dys)function","volume":"200","author":"Deruyver","year":"2016","journal-title":"Auton Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib318","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/bju.12876","article-title":"Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (LUTS): myth or reality?","volume":"115","author":"Deruyver","year":"2015","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib319","article-title":"Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics)","volume":"12","author":"Deshpande","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib320","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/WNF.0b013e3182613dce","article-title":"Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study","volume":"35","author":"Di Rezze","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib321","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.sleep.2007.07.019","article-title":"Effect of tolterodine on sleep structure modulated by CYP2D6 genotype","volume":"9","author":"Diefenbach","year":"2008","journal-title":"Sleep Med"},{"key":"10.1124\/pharmrev.121.000523_bib322","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/nau.10099","article-title":"Overactive bladder symptoms: do we need urodynamics?","volume":"22","author":"Digesu","year":"2003","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib323","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.urology.2012.03.035","article-title":"Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity","volume":"80","author":"Digesu","year":"2012","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib324","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s11255-017-1671-2","article-title":"Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast","volume":"49","author":"Ding","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib325","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11255-018-2038-z","article-title":"The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats","volume":"51","author":"Ding","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib326","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2004.01.016","article-title":"Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: a pilot study","volume":"46","author":"Dinis","year":"2004","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib327","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/pharmrev.121.000523_bib328","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.ju.0000070404.24755.35","article-title":"Prevalence and outcomes of continence surgery in community dwelling women","volume":"170","author":"Diokno","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib329","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib330","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0022-5347(05)64684-8","article-title":"Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence","volume":"168","author":"Dmochowski","year":"2002","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib331","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/01.ju.0000080708.87092.cc","article-title":"Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence","volume":"170","author":"Dmochowski","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib332","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00345-005-0012-8","article-title":"Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials","volume":"23","author":"Dmochowski","year":"2005","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib333","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urology.2009.09.018","article-title":"Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder","volume":"75","author":"Dmochowski","year":"2010","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib334","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib335","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/nau.24536","article-title":"Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis","volume":"40","author":"Dmochowski","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib336","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/nau.24122","article-title":"Spontaneous voiding is surprisingly recoverable via outlet procedure in men with underactive bladder and documented detrusor underactivity on urodynamics","volume":"38","author":"Dobberfuhl","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.121.000523_bib337","first-page":"S14","article-title":"Chapter 3: molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A","volume":"33","author":"Dolly","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib338","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/luts.12297","article-title":"How long does the effect of botulinum toxin in neurogenic patients last? An analysis of the subset of \u201cgood responders.\u201d","volume":"12","author":"Dominique","year":"2020","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib339","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"10.1124\/pharmrev.121.000523_bib340","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/nau.23423","article-title":"Tadalafil attenuates hypotonicity-induced Ca2+ influx via TRPV2 and TRPV4 in primary rat bladder urothelial cell cultures","volume":"37","author":"Dong","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib341","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000280025","article-title":"Action of beta-adrenergic blocking agents on the urethral pressure profile","volume":"31","author":"Donker","year":"1976","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib342","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","article-title":"Clinical pharmacokinetics of trospium chloride","volume":"44","author":"Doroshyenko","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pharmrev.121.000523_bib343","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF00558247","article-title":"The pharmacokinetics of oxybutynin in man","volume":"35","author":"Douchamps","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib344","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrurol.2010.187","article-title":"Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity","volume":"7","author":"Dowson","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"Suppl 6","key":"10.1124\/pharmrev.121.000523_bib345","first-page":"S13","article-title":"Fundamentals of terminology in lower urinary tract function","volume":"37","author":"Drake","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib346","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","article-title":"Efficacy and safety of mirabegon add-on therapy to solifenacin in incontinent overactive bladder patients with an iInadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE)","volume":"70","author":"Drake","year":"2016","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib347","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eururo.2014.07.013","article-title":"Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension","volume":"67","author":"Drake","year":"2015","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib348","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1464-410X.2005.05455.x","article-title":"Localized contractions in the normal human bladder and in urinary urgency","volume":"95","author":"Drake","year":"2005","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib349","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.13945","article-title":"Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis","volume":"120","author":"Drake","year":"2017","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib350","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.juro.2013.08.027","article-title":"Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial","volume":"191","author":"Dubeau","year":"2014","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib351","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00192-005-0063-9","article-title":"Duloxetine treatment for women awaiting continence surgery","volume":"17","author":"Duckett","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib352","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005493.pub3","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","volume":"12","author":"Duthie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib353","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/nau.20620","article-title":"Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study","volume":"27","author":"Dwyer","year":"2008","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib354","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00192-003-1099-3","article-title":"Treatment of overactive bladder with botulinum toxin type B: a pilot study","volume":"14","author":"Dykstra","year":"2003","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib355","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib356","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00210-015-1122-5","article-title":"The expression of \u03b23-adrenoceptor and muscarinic type 3 receptor immuno-reactivity in the major pelvic ganglion of the rat","volume":"388","author":"Eastham","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib357","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1464-410X.1995.tb07745.x","article-title":"An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia","volume":"76","author":"Eckford","year":"1995","journal-title":"Br J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib358","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1464-410X.1994.tb07116.x","article-title":"Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis","volume":"74","author":"Eckford","year":"1994","journal-title":"Br J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib359","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","article-title":"Discovery of vibegron: a potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder","volume":"59","author":"Edmondson","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.121.000523_bib360","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/jpet.107.121756","article-title":"Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder","volume":"322","author":"Ehlert","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib361","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","article-title":"Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study","volume":"41","author":"Ehren","year":"2007","journal-title":"Scand J Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib362","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1002\/nau.23786","article-title":"A systematic review of urinary bladder hypertrophy in experimental diabetes: part 2. Comparison of animal models and functional consequences","volume":"37","author":"Ellenbroek","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib363","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/SPV.0000000000000256","article-title":"Combined tolterodine and vaginal estradiol cream for overactive bladder symptoms after randomized single-therapy treatment","volume":"22","author":"Ellington","year":"2016","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1124\/pharmrev.121.000523_bib364","doi-asserted-by":"crossref","first-page":"838","DOI":"10.5414\/CP201782","article-title":"Single dose pharmacokinetics and absolute bioavailability of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder","volume":"50","author":"Eltink","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000523_bib365","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/PL00004024","article-title":"Effect of estrogen-progestogen hormonal replacement therapy on periurethral and bladder vessels","volume":"11","author":"Endo","year":"2000","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib366","series-title":"Good Research Practice in Non-Clinical Pharmacology and Biomedicine","first-page":"163","article-title":"Building robustness into translational research","author":"Erdogan","year":"2020"},{"key":"10.1124\/pharmrev.121.000523_bib367","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00210-022-02221-7","article-title":"Does coupling to ADP ribosylation factor 6 explain differences between muscarinic and other receptors in interaction with \u03b2-adrenoceptor-mediated smooth muscle relaxation?","volume":"395","author":"Erdogan","year":"2022","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib368","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000519720","article-title":"Validation of fenoterol to study \u03b22-adrenoceptor function in the rat urinary bladder","volume":"107","author":"Erdogan","year":"2022","journal-title":"Pharmacology"},{"key":"10.1124\/pharmrev.121.000523_bib369","doi-asserted-by":"crossref","first-page":"19084","DOI":"10.1073\/pnas.1005333107","article-title":"Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis","volume":"107","author":"Everaerts","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.121.000523_bib370","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/00016349808565820","article-title":"Paraurethral connective tissue in stress-incontinent women after menopause","volume":"77","author":"Falconer","year":"1998","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1124\/pharmrev.121.000523_bib371","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1113\/jphysiol.1990.sp018172","article-title":"A bladder-to-bladder cooling reflex in the cat","volume":"427","author":"Fall","year":"1990","journal-title":"J Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib372","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0029-7844(96)00281-5","article-title":"Efficacy of estrogen supplementation in the treatment of urinary incontinence","volume":"88","author":"Fantl","year":"1996","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib373","first-page":"12","article-title":"Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee","volume":"83","author":"Fantl","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib374","first-page":"1996","article-title":"Urinary incontinence in adults: acute and chronic management","volume":"2","author":"Fantl","year":"1996","journal-title":"Clinical Practice Guideline"},{"key":"10.1124\/pharmrev.121.000523_bib375","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","article-title":"Onabotulinum toxin A injections in men with refractory idiopathic detrusor overactivity","volume":"123","author":"Faure Walker","year":"2019","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib376","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1748-1716.1980.tb06569.x","article-title":"Functional and metabolic effects of terbutaline and propranolol in fast- and slow-contracting skeletal muscle in vitro","volume":"109","author":"Fellenius","year":"1980","journal-title":"Acta Physiol Scand"},{"key":"10.1124\/pharmrev.121.000523_bib377","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049516","article-title":"Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay","volume":"7","author":"Fern\u00e1ndez-Salas","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib378","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000368618","article-title":"Improvement of continence rate with pelvic floor muscle training post-prostatectomy: a meta-analysis of randomized controlled trials","volume":"94","author":"Fern\u00e1ndez","year":"2015","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib379","doi-asserted-by":"crossref","first-page":"eAO4207","DOI":"10.1590\/s1679-45082018ao4207","article-title":"Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial","volume":"16","author":"Ferreira","year":"2018","journal-title":"Einstein (Sao Paulo)"},{"key":"10.1124\/pharmrev.121.000523_bib380","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1517\/13543776.2012.711320","article-title":"Advances in modulating thermosensory TRP channels","volume":"22","author":"Ferrer-Montiel","year":"2012","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/pharmrev.121.000523_bib381","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s002100000338","article-title":"Modulation of noradrenaline-induced microvascular constriction by protein kinase inhibitors","volume":"363","author":"Fetscher","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib382","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bjp.0704781","article-title":"M(3) muscarinic receptors mediate contraction of human urinary bladder","volume":"136","author":"Fetscher","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib383","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1743-6109.2009.01511.x","article-title":"Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract","volume":"7","author":"Fibbi","year":"2010","journal-title":"J Sex Med"},{"key":"10.1124\/pharmrev.121.000523_bib384","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.eururo.2006.08.005","article-title":"Pharmacologic treatment in postprostatectomy stress urinary incontinence","volume":"51","author":"Filocamo","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib385","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.juro.2013.05.058","article-title":"The efficacy and safety of combined therapy with \u03b1-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis","volume":"190","author":"Filson","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib386","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1464-410X.2006.06258.x","article-title":"Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?","volume":"98","author":"Finney","year":"2006","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib387","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib388","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eururo.2005.05.009","article-title":"Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist","volume":"48","author":"Foote","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib389","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/978-3-642-16499-6_22","article-title":"ATP and P2X purinoceptors in urinary tract disorders","volume":"202","author":"Ford","year":"2011","journal-title":"Handb Exp Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.121.000523_bib390","first-page":"S132","article-title":"Purinoceptors as therapeutic targets for lower urinary tract dysfunction","volume":"147","author":"Ford","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib391","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fncel.2013.00267","article-title":"The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders","volume":"7","author":"Ford","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib392","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/jnnp.57.2.169","article-title":"Intravesical capsaicin for treatment of detrusor hyperreflexia","volume":"57","author":"Fowler","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/pharmrev.121.000523_bib393","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrn2401","article-title":"The neural control of micturition","volume":"9","author":"Fowler","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib394","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0140-6736(92)91186-C","article-title":"Intravesical capsaicin for neurogenic bladder dysfunction","volume":"339","author":"Fowler","year":"1992","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.121.000523_bib395","doi-asserted-by":"crossref","first-page":"180.e1","DOI":"10.1016\/j.jpurol.2019.12.012","article-title":"Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies","volume":"16","author":"Franco","year":"2020","journal-title":"J Pediatr Urol"},{"key":"10.1124\/pharmrev.121.000523_bib396","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.juro.2007.03.185","article-title":"The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children","volume":"178","author":"Franco","year":"2007","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib397","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13937","article-title":"Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study","volume":"75","author":"Frankel","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib398","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.107.125393","article-title":"Does phospholipase C mediate muscarinic receptor-induced rat urinary bladder contraction?","volume":"322","author":"Frazier","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib399","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.104.077768","article-title":"Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol?","volume":"313","author":"Frazier","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib400","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-007-0208-0","article-title":"Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and \u03b2-adrenoceptors","volume":"377","author":"Frazier","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib401","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.1996.tb00035.x","article-title":"Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis","volume":"94","author":"Fredrikson","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1124\/pharmrev.121.000523_bib402","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002165","article-title":"The economics of reproducibility in preclinical research","volume":"13","author":"Freedman","year":"2015","journal-title":"PLoS Biol"},{"key":"10.1124\/pharmrev.121.000523_bib403","first-page":"605","article-title":"Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine","volume":"102","author":"Freeman","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib404","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","article-title":"The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)","volume":"17","author":"Freeman","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib405","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2010.03.147","article-title":"A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder","volume":"184","author":"Frenkl","year":"2010","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib406","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/j.1476-5381.1995.tb16378.x","article-title":"A role for Q type Ca2+ channels in neurotransmission in the rat urinary bladder","volume":"116","author":"Frew","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib407","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5414\/CPP40295","article-title":"Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily","volume":"40","author":"Fr\u00f6hlich","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000523_bib408","first-page":"486","article-title":"[Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test]","volume":"48","author":"Fr\u00f6hlich","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/pharmrev.121.000523_bib409","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.vascn.2004.03.002","article-title":"Experimental models to study the physiology, pathophysiology, and pharmacology of the lower urinary tract","volume":"49","author":"Fry","year":"2004","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/pharmrev.121.000523_bib410","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1111\/j.1464-410X.2010.09845.x","article-title":"Influence of age and bladder dysfunction on the contractile properties of isolated human detrusor smooth muscle","volume":"108","author":"Fry","year":"2011","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib411","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-981-13-5895-1_5","article-title":"Spontaneous activity and the urinary bladder","volume":"1124","author":"Fry","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/pharmrev.121.000523_bib412","doi-asserted-by":"crossref","first-page":"102852","DOI":"10.1016\/j.autneu.2021.102852","article-title":"Purinergic signalling in the urinary bladder\u2014when function becomes dysfunction","volume":"235","author":"Fry","year":"2021","journal-title":"Auton Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib413","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jpedsurg.2019.10.044","article-title":"Effectiveness and tolerability of mirabegron in children with overactive bladder: a retrospective pilot study","volume":"55","author":"Fryer","year":"2020","journal-title":"J Pediatr Surg"},{"key":"10.1124\/pharmrev.121.000523_bib414","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00192-003-1042-7","article-title":"Expression of estrogen receptor-alpha and -beta in anterior vaginal walls of genuine stress incontinent women","volume":"14","author":"Fu","year":"2003","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib415","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11255-017-1509-y","article-title":"Mechanisms of inhibitory action of TRK-130 (Naltalimide), a \u03bc-opioid receptor partial agonist, on the micturition reflex","volume":"49","author":"Fujimura","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib416","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/jpet.114.214031","article-title":"Characteristics of TRK-130 (Naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder","volume":"350","author":"Fujimura","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib417","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(01)61994-3","article-title":"Expression and possible functional role of the \u03b23-adrenoceptor in human and rat detrusor muscle","volume":"161","author":"Fujimura","year":"1999","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib418","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2013.01.018","article-title":"Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms","volume":"64","author":"F\u00fcllhase","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib419","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/nau.22753","article-title":"Spinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats","volume":"35","author":"F\u00fcllhase","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib420","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/nau.21071","article-title":"Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction","volume":"30","author":"F\u00fcllhase","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib421","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.juro.2008.11.008","article-title":"Role of \u03b12-adrenoceptors and glutamate mechanisms in the external urethral sphincter continence reflex in rats","volume":"181","author":"Furuta","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib422","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.juro.2013.01.061","article-title":"Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia","volume":"190","author":"Fwu","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib423","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1006903507321","article-title":"Distribution of afferent axons in the bladder of rats","volume":"27","author":"Gabella","year":"1998","journal-title":"J Neurocytol"},{"key":"10.1124\/pharmrev.121.000523_bib424","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","article-title":"Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"70","author":"Gacci","year":"2016","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib425","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2007.08.039","article-title":"Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections","volume":"53","author":"Gam\u00e9","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib426","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40272-020-00401-7","article-title":"Pediatric pharmacology of desmopressin in children with enuresis:aA comprehensive review","volume":"22","author":"Gasthuys","year":"2020","journal-title":"Paediatr Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib427","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1067\/mob.2001.119627","article-title":"Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women","volume":"185","author":"Gebhart","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib428","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0022-5347(01)66793-4","article-title":"Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia","volume":"154","author":"Geirsson","year":"1995","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib429","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1100\/tsw.2007.271","article-title":"The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury","volume":"7","author":"George","year":"2007","journal-title":"ScientificWorldJournal"},{"key":"10.1124\/pharmrev.121.000523_bib430","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1172\/JCI31766","article-title":"Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding","volume":"117","author":"Gevaert","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.121.000523_bib431","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.027144","article-title":"The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride","volume":"37","author":"Geyer","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.121.000523_bib432","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/01.ju.0000154167.90600.c6","article-title":"A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence","volume":"173","author":"Ghoniem","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib433","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0022-5347(06)00258-8","article-title":"Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity","volume":"175","author":"Giannantoni","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib434","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.ju.0000132152.53532.5d","article-title":"Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study","volume":"172","author":"Giannantoni","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib435","first-page":"625","article-title":"IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial","volume":"74","author":"Giannantoni","year":"2021","journal-title":"Minerva Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib436","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/14737167.2015.1011132","article-title":"A review of cost-effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?","volume":"15","author":"Giannitsas","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1124\/pharmrev.121.000523_bib437","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euf.2017.08.008","article-title":"Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study","volume":"3","author":"Gibson","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1124\/pharmrev.121.000523_bib438","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0022-5347(17)49941-1","article-title":"Conservative treatment of female stress incontinence with imipramine","volume":"132","author":"Gilja","year":"1984","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib439","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1464-410X.2003.04727.x","article-title":"The actions of sodium nitroprusside and the phosphodiesterase inhibitor dipyridamole on phasic activity in the isolated guinea-pig bladder","volume":"93","author":"Gillespie","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib440","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1111\/j.1464-410X.2012.11240.x","article-title":"Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the \u03b2(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction","volume":"110","author":"Gillespie","year":"2012","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib441","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv Ther"},{"key":"10.1124\/pharmrev.121.000523_bib442","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib443","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bju.12174","article-title":"Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder","volume":"112","author":"Ginsberg","year":"2013","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib444","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.juro.2017.05.068","article-title":"Long-term treatment with onabotulinumtoxinA results in consistent, durable improvements in health related quality of life in patients with overactive bladder","volume":"198","author":"Ginsberg","year":"2017","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib445","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2012.09.006","article-title":"The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"63","author":"Giuliano","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib446","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00192-011-1411-6","article-title":"Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity","volume":"22","author":"Glavind","year":"2011","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib447","article-title":"Desmopressin for nocturnal enuresis in children","volume":"3","author":"Glazener","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib448","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(17)59648-2","article-title":"The urethral continence zone and its relation to stress incontinence","volume":"112","author":"Gleason","year":"1974","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib449","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jpurol.2013.12.017","article-title":"Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration","volume":"10","author":"Gleason","year":"2014","journal-title":"J Pediatr Urol"},{"key":"10.1124\/pharmrev.121.000523_bib450","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s002400050038","article-title":"Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation","volume":"26","author":"Goepel","year":"1998","journal-title":"Urol Res"},{"key":"10.1124\/pharmrev.121.000523_bib451","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/nau.22504","article-title":"Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and\/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study","volume":"34","author":"Goldfischer","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib452","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MOU.0000000000000489","article-title":"Combination treatment for male lower urinary tract symptoms with anticholinergic and alpha-blockers","volume":"28","author":"Gomelsky","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1124\/pharmrev.121.000523_bib453","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1590\/S1677-55382010000100011","article-title":"Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity","volume":"36","author":"Gomes","year":"2010","journal-title":"Int Braz J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib454","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00228-011-1090-8","article-title":"Comparative adherence to oxybutynin or tolterodine among older patients","volume":"68","author":"Gomes","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib455","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1185\/03007995.2015.1074067","article-title":"Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis","volume":"31","author":"Gong","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pharmrev.121.000523_bib456","doi-asserted-by":"crossref","first-page":"104724","DOI":"10.1016\/j.phrs.2020.104724","article-title":"Urinary bladder sigma-1 receptors: a new target for cystitis treatment","volume":"155","author":"Gonz\u00e1lez-Cano","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1124\/pharmrev.121.000523_bib457","first-page":"65","article-title":"Comparative effectiveness of anticholinergic agents for lower urinary tract symptoms","volume":"24","author":"Goodson","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1124\/pharmrev.121.000523_bib458","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14728222.8.5.437","article-title":"Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders","volume":"8","author":"Gopalakrishnan","year":"2004","journal-title":"Expert Opin Ther Targets"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000523_bib459","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000052314","article-title":"The distribution of noradrenergic nerves in the human lower urinary tract. A review","volume":"36","author":"Gosling","year":"1999","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib460","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1442-2042.2011.02732.x","article-title":"Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial","volume":"18","author":"Gotoh","year":"2011","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib461","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40256-018-00320-6","article-title":"Clinical pharmacokinetics, safety, and tolerability of a novel, first-in-class TRPV4 ion channel inhibitor, GSK2798745, in healthy and heart failure subjects","volume":"19","author":"Goyal","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib462","first-page":"116","article-title":"Postmenopausal hormones and incontinence: the Heart and Estrogen\/Progestin Replacement Study","volume":"97","author":"Grady","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib463","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.juro.2008.11.079","article-title":"Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder","volume":"181","author":"Gratzke","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib464","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.juro.2010.09.080","article-title":"Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction","volume":"185","author":"Gratzke","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib465","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.eururo.2010.02.027","article-title":"Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats","volume":"57","author":"Gratzke","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib466","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib467","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1124\/pharmrev.121.000523_bib468","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.juro.2006.08.018","article-title":"Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence","volume":"176","author":"Green","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib469","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","article-title":"Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)","volume":"20","author":"Griebling","year":"2020","journal-title":"BMC Geriatr"},{"issue":"6, Suppl","key":"10.1124\/pharmrev.121.000523_bib470","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/nau.20488","article-title":"Imaging bladder sensations","volume":"26","author":"Griffiths","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib471","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/nau.20549","article-title":"Bladder control, urgency, and urge incontinence: evidence from functional brain imaging","volume":"27","author":"Griffiths","year":"2008","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib472","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-642-16499-6_5","article-title":"Use of functional imaging to monitor central control of voiding in humans","volume":"202","author":"Griffiths","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib473","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.eururo.2010.06.035","article-title":"Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses","volume":"58","author":"Grise","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib474","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.AOG.0000107290.33034.6f","article-title":"Postmenopausal hormone therapy and risk of developing urinary incontinence","volume":"103","author":"Grodstein","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246042","article-title":"A systematic review and activation likelihood estimation meta-analysis of the central innervation of the lower urinary tract: pelvic floor motor control and micturition","volume":"16","author":"Groenendijk","year":"2021","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib476","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.juro.2010.12.031","article-title":"M3 muscarinic receptor-like immunoreactivity in sham operated and obstructed guinea pig bladders","volume":"185","author":"Grol","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib477","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","article-title":"Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence","volume":"47","author":"Grosse","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib478","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/bcpt.12785","article-title":"Inhibitory effects of urothelium-related factors","volume":"121","author":"Guan","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.121.000523_bib479","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2165\/00003088-200342140-00004","article-title":"Clinical pharmacokinetics of drugs used to treat urge incontinence","volume":"42","author":"Guay","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pharmrev.121.000523_bib480","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.juro.2008.05.056","article-title":"Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review","volume":"180","author":"Guerra","year":"2008","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib481","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1432-1033.1994.00761.x","article-title":"Antibodies for the immunochemistry of the human \u03b2 3-adrenergic receptor","volume":"224","author":"Guillaume","year":"1994","journal-title":"Eur J Biochem"},{"key":"10.1124\/pharmrev.121.000523_bib482","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/nau.22406","article-title":"Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder","volume":"33","author":"Haab","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib483","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib484","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1464-410X.2006.06439.x","article-title":"Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study","volume":"98","author":"Haab","year":"2006","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib485","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib486","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1113\/jphysiol.1990.sp018117","article-title":"Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat","volume":"425","author":"H\u00e4bler","year":"1990","journal-title":"J Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib487","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-020-01622-8","article-title":"Nocturia in patients with cognitive dysfunction: a systematic review of the literature","volume":"20","author":"Haddad","year":"2020","journal-title":"BMC Geriatr"},{"key":"10.1124\/pharmrev.121.000523_bib488","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2004.07.011","article-title":"Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder","volume":"46","author":"Haferkamp","year":"2004","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib489","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00192-020-04516-w","article-title":"A randomized, intervention parallel multicentre study to evaluate duloxetine and innovative pelvic floor muscle training in women with uncomplicated stress urinary incontinence-the DULOXING study","volume":"32","author":"Hagovska","year":"2021","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib490","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.23869","article-title":"Management of neurogenic bladder in patients with Parkinson\u2019s disease: a systematic review","volume":"38","author":"Hajebrahimi","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib491","article-title":"Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK","volume":"6","author":"Hakimi","year":"2018","journal-title":"J Mark Access Health Policy"},{"key":"10.1124\/pharmrev.121.000523_bib492","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00345-018-2301-z","article-title":"Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury","volume":"36","author":"Hamid","year":"2018","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib493","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00192-020-04423-0","article-title":"OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice","volume":"32","author":"Hamid","year":"2021","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib494","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/luts.12048","article-title":"Bladder hyperactivity induced by chronic variable stress in rats","volume":"7","author":"Han","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib495","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/nau.22809","article-title":"Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014","volume":"35","author":"Hanna-Mitchell","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib496","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/nau.22508","article-title":"Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium","volume":"34","author":"Hanna-Mitchell","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib497","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00192-016-3223-1","article-title":"Impaired contraction and decreased detrusor innervation in a female rat model of pelvic neuropraxia","volume":"28","author":"Hannan","year":"2017","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib498","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.urology.2013.10.034","article-title":"Antimuscarinics and \u03b1-blockers or \u03b1-blockers monotherapy on lower urinary tract symptoms\u2014a meta-analysis","volume":"83","author":"Hao","year":"2014","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib499","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1464-410X.2003.04312.x","article-title":"A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity","volume":"92","author":"Harper","year":"2003","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib500","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/nau.24147","article-title":"Detrusor underactivity in women: a current understanding","volume":"38","author":"Hartigan","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib501","first-page":"1459","article-title":"Effects of propiverine hydrochloride on the spontaneous contractions of isolated guinea-pig urinary bladder strip and rhythmic urinary bladder contractions of anesthetized dog","volume":"42","author":"Haruno","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/pharmrev.121.000523_bib502","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JU.0000000000000656","article-title":"Cost-effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: Results of the ROSETTA randomized trial","volume":"203","author":"Harvie","year":"2020","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib503","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00003495-200666050-00002","article-title":"Pharmacological management of women with mixed urinary incontinence","volume":"66","author":"Hashim","year":"2006","journal-title":"Drugs"},{"issue":"Suppl 6","key":"10.1124\/pharmrev.121.000523_bib504","first-page":"S20","article-title":"Basic concepts in nocturia, based on International Continence Society standards in nocturnal lower urinary tract function","volume":"37","author":"Hashim","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib505","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/nau.20613","article-title":"Desmopressin, as a \u201cdesigner-drug,\u201d in the treatment of overactive bladder syndrome","volume":"28","author":"Hashim","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib506","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0014-2999(93)90451-M","article-title":"Nitric oxide-dependent and -independent neurogenic relaxation of isolated dog urethra","volume":"231","author":"Hashimoto","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib507","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.ju.0000168616.71956.a4","article-title":"Effects of the selective acetylcholinesterase inhibitor TAK-802 on the voiding behavior and bladder mass increase in rats with partial bladder outlet obstruction","volume":"174","author":"Hashimoto","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib508","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00210-012-0814-3","article-title":"Effect of mirabegron, a novel \u03b23-adrenoceptor agonist, on bladder function during storage phase in rats","volume":"386","author":"Hatanaka","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib509","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00210-013-0900-1","article-title":"Pharmacological profile of the selective \u03b23-adrenoceptor agonist mirabegron in cynomolgus monkeys","volume":"386","author":"Hatanaka","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib510","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjp.0703068","article-title":"Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro","volume":"129","author":"Hawthorn","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib511","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neures.2009.07.005","article-title":"Expression of the TRPM8-immunoreactivity in dorsal root ganglion neurons innervating the rat urinary bladder","volume":"65","author":"Hayashi","year":"2009","journal-title":"Neurosci Res"},{"key":"10.1124\/pharmrev.121.000523_bib512","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib513","doi-asserted-by":"crossref","first-page":"13181","DOI":"10.1111\/jcmm.15926","article-title":"Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder","volume":"24","author":"He","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1124\/pharmrev.121.000523_bib514","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41393-019-0411-0","article-title":"Long term continuation with repeated botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury","volume":"58","author":"Hebert","year":"2020","journal-title":"Spinal Cord"},{"key":"10.1124\/pharmrev.121.000523_bib515","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/nau.22442","article-title":"Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction","volume":"33","author":"Hedlund","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib516","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrurol.2016.110","article-title":"The endocannabinoid system\u2014a target for the treatment of LUTS?","volume":"13","author":"Hedlund","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.121.000523_bib517","first-page":"S80","article-title":"Muscarinic receptors in the bladder: from basic research to therapeutics","volume":"147","author":"Hegde","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib518","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/sj.bjp.0701048","article-title":"Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo","volume":"120","author":"Hegde","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib519","first-page":"40","article-title":"Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies","volume":"5","author":"Hegde","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib520","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.eururo.2009.12.025","article-title":"A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients","volume":"57","author":"Helfand","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib521","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.293.8.935","article-title":"Effects of estrogen with and without progestin on urinary incontinence","volume":"293","author":"Hendrix","year":"2005","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.121.000523_bib522","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3389\/fphys.2018.00734","article-title":"Inhibition of prostate smooth muscle contraction by inhibitors of Polo-like kinases","volume":"9","author":"Hennenberg","year":"2018","journal-title":"Front Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib523","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2017.03.022","article-title":"Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region","volume":"803","author":"Hennenberg","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib524","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","article-title":"Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review","volume":"326","author":"Herbison","year":"2003","journal-title":"BMJ"},{"key":"10.1124\/pharmrev.121.000523_bib525","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b23 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib526","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib527","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib528","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1464-410X.2007.07198.x","article-title":"A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey","volume":"101","author":"Herschorn","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib529","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.juro.2017.01.069","article-title":"The efficacy and safety of onabotulinumtoxinA or solifenacin compared with placebo in solifenacin na\u00efve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial","volume":"198","author":"Herschorn","year":"2017","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib530","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40266-020-00783-w","article-title":"Safety and tolerability results from the PILLAR study: a phase IV, double-blind, randomized, placebo-controlled study of mirabegron in patients\u2009\u2265\u200965 years with overactive bladder-wet","volume":"37","author":"Herschorn","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1124\/pharmrev.121.000523_bib531","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0378-5122(00)00143-2","article-title":"Oestrogens and lower urinary tract function","volume":"36","author":"Hextall","year":"2000","journal-title":"Maturitas"},{"key":"10.1124\/pharmrev.121.000523_bib532","first-page":"1193","article-title":"The impact of the menstrual cycle on urinary symptoms and the results of urodynamic investigation","volume":"108","author":"Hextall","year":"2001","journal-title":"BJOG"},{"key":"10.1124\/pharmrev.121.000523_bib533","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/jpet.107.125757","article-title":"GW427353 (solabegron), a novel, selective \u03b23-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog","volume":"323","author":"Hicks","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib534","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0031-6997(25)06845-0","article-title":"International Union of Pharmacology. X. Recommendation for nomenclature of \u03b1 1-adrenoceptors: consensus update","volume":"47","author":"Hieble","year":"1995","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib535","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1185\/030079907X233160","article-title":"Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study","volume":"23","author":"Hill","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pharmrev.121.000523_bib536","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00345-015-1599-z","article-title":"Considerations in the modern management of stress urinary incontinence resulting from intrinsic sphincter deficiency","volume":"33","author":"Hillary","year":"2015","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib537","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jnnp.46.9.854","article-title":"The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis","volume":"46","author":"Hilton","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/pharmrev.121.000523_bib538","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1464-410X.1982.tb06969.x","article-title":"The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female","volume":"54","author":"Hilton","year":"1982","journal-title":"Br J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib539","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2006.09.005","article-title":"Botulinum toxin B is not an effective treatment of refractory overactive bladder","volume":"69","author":"Hirst","year":"2007","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib540","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0022-5347(06)00301-6","article-title":"The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor","volume":"176","author":"Hoebeke","year":"2006","journal-title":"J Urol"},{"issue":"4, Suppl","key":"10.1124\/pharmrev.121.000523_bib541","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.juro.2009.05.100","article-title":"Solifenacin for therapy resistant overactive bladder","volume":"182","author":"Hoebeke","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib542","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1464-410x.2000.00833.x","article-title":"The pharmacology of paediatric incontinence","volume":"86","author":"Hoebeke","year":"2000","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib543","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.juro.2013.05.049","article-title":"Increased mRNA expression of genes involved in pronociceptive inflammatory reactions in bladder tissue of interstitial cystitis","volume":"190","author":"Homma","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib544","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1442-2042.2008.02152.x","article-title":"Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib545","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1442-2042.2009.02286.x","article-title":"A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"16","author":"Homma","year":"2009","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib546","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1442-2042.2008.02104.x","article-title":"A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib547","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s11255-016-1329-5","article-title":"Anandamide transporter-mediated regulation of the micturition reflex in urethane-anesthetized rats","volume":"48","author":"Honda","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib548","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/nau.20289","article-title":"Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage","volume":"25","author":"Horstmann","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib549","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2170\/jjphysiol.45.823","article-title":"The effects of aging on the rat bladder and its innervation","volume":"45","author":"Hotta","year":"1995","journal-title":"Jpn J Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135185","article-title":"Gentle mechanical skin stimulation inhibits micturition contractions via the spinal opioidergic system and by decreasing both ascending and descending transmissions of the micturition reflex in the spinal cord","volume":"10","author":"Hotta","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib551","doi-asserted-by":"crossref","first-page":"114363","DOI":"10.1016\/j.bcp.2020.114363","article-title":"PGE2 receptors in detrusor muscle: drugging the undruggable for urgency","volume":"184","author":"Hou","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib552","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.65.5.778","article-title":"Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis","volume":"65","author":"Hoverd","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/pharmrev.121.000523_bib553","doi-asserted-by":"crossref","first-page":"C600","DOI":"10.1152\/ajpcell.00270.2015","article-title":"Novel regulatory mechanism in human urinary bladder: central role of transient receptor potential melastatin 4 channels in detrusor smooth muscle function","volume":"310","author":"Hristov","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib554","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neurad.2007.11.008","article-title":"Identification of brain structures involved in micturition with functional magnetic resonance imaging (fMRI)","volume":"35","author":"Hruz","year":"2008","journal-title":"J Neuroradiol"},{"key":"10.1124\/pharmrev.121.000523_bib555","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1447-0756.2010.01493.x","article-title":"Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome","volume":"37","author":"Hsiao","year":"2011","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1124\/pharmrev.121.000523_bib556","doi-asserted-by":"crossref","first-page":"666047","DOI":"10.3389\/fphar.2021.666047","article-title":"Concentration-dependent alpha1-adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by mirabegron in the human prostate","volume":"12","author":"Huang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib557","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/jpet.121.001029","article-title":"Inhibition of full smooth muscle contraction in isolated human detrusor tissues by mirabegron is limited to off-target inhibition of neurogenic contractions","volume":"381","author":"Huang","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib558","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0014-2999(00)00229-6","article-title":"K(ATP) channels mediate the beta(2)-adrenoceptor agonist-induced relaxation of rat detrusor muscle","volume":"397","author":"Hudman","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib559","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00498259209053145","article-title":"Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers","volume":"22","author":"Hughes","year":"1992","journal-title":"Xenobiotica"},{"key":"10.1124\/pharmrev.121.000523_bib560","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0300-9084(00)00216-9","article-title":"How botulinum and tetanus neurotoxins block neurotransmitter release","volume":"82","author":"Humeau","year":"2000","journal-title":"Biochimie"},{"key":"10.1124\/pharmrev.121.000523_bib561","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s002400100175","article-title":"Clinical options for imipramine in the management of urinary incontinence","volume":"29","author":"Hunsballe","year":"2001","journal-title":"Urol Res"},{"key":"10.1124\/pharmrev.121.000523_bib562","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0022-5347(05)65982-4","article-title":"Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings","volume":"166","author":"Hyman","year":"2001","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib563","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","article-title":"A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction","volume":"193","author":"Ichihara","year":"2015","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib564","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/bph.14658","article-title":"\u03b23 -Adrenoceptors in the normal and diseased urinary bladder\u2014what are the open questions?","volume":"176","author":"Igawa","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib565","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00210-012-0824-1","article-title":"Pharmacological profile of \u03b23-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome","volume":"386","author":"Igawa","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib566","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00467-020-04594-4","article-title":"Neurophysiological control of urinary bladder storage and voiding-functional changes through development and pathology","volume":"36","author":"Ikeda","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib567","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.eururo.2012.03.031","article-title":"Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder","volume":"62","author":"Ikeda","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib568","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bph.15299","article-title":"Update of P2X receptor properties and their pharmacology: IUPHAR Review 30","volume":"178","author":"Illes","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib569","doi-asserted-by":"crossref","first-page":"32.e1","DOI":"10.1016\/j.jpurol.2018.08.007","article-title":"Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes","volume":"15","author":"Ingham","year":"2019","journal-title":"J Pediatr Urol"},{"key":"10.1124\/pharmrev.121.000523_bib570","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.bbamem.2006.09.029","article-title":"Impact of GPCRs in clinical medicine: genetic variants and drug targets","volume":"1768","author":"Insel","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/pharmrev.121.000523_bib572","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1464-410X.2008.07573.x","article-title":"Understanding the elements of overactive bladder: questions raised by the EPIC study","volume":"101","author":"Irwin","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib573","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib574","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.eururo.2008.01.027","article-title":"Symptom bother and health care-seeking behavior among individuals with overactive bladder","volume":"53","author":"Irwin","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib575","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.urology.2021.01.021","article-title":"Efficacy and safety of vibegron add-on therapy in men with persistent storage symptoms after receiving alpha 1-blocker or phosphodiesterase 5 inhibitor: a preliminary study","volume":"153","author":"Ishikawa","year":"2021","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib576","first-page":"213","article-title":"Hormone replacement therapy plus pelvic floor muscle exercise for postmenopausal stress incontinence. A randomized, controlled trial","volume":"46","author":"Ishiko","year":"2001","journal-title":"J Reprod Med"},{"key":"10.1124\/pharmrev.121.000523_bib577","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0020-7292(00)00254-X","article-title":"Beta(2)-adrenergic agonists and pelvic floor exercises for female stress incontinence","volume":"71","author":"Ishiko","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1124\/pharmrev.121.000523_bib578","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.juro.2014.11.005","article-title":"Long-term caloric restriction in rats may prevent age related impairment of in vitro bladder function","volume":"193","author":"Ito","year":"2015","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib579","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bju.13225","article-title":"Functional role of the transient receptor potential melastatin 8 (TRPM8) ion channel in the urinary bladder assessed by conscious cystometry and ex vivo measurements of single-unit mechanosensitive bladder afferent activities in the rat","volume":"117","author":"Ito","year":"2016","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib580","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/bju.14664","article-title":"Sildenafil, a phosphodiesterase type 5 inhibitor, augments sphincter bursting and bladder afferent activity to enhance storage function and voiding efficiency in mice","volume":"124","author":"Ito","year":"2019","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib581","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.juro.2016.05.104","article-title":"Preventive effects of long-term caloric restriction on aging related in vivo bladder dysfunction and molecular biological changes in the bladder and dorsal root ganglia in rats","volume":"196","author":"Ito","year":"2016","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib582","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003369","article-title":"Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT\/A)","volume":"9","author":"Jacky","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1124\/pharmrev.121.000523_bib583","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0079-6123(08)62758-2","article-title":"Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception","volume":"67","author":"J\u00e4nig","year":"1986","journal-title":"Prog Brain Res"},{"key":"10.1124\/pharmrev.121.000523_bib584","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.juro.2011.04.107","article-title":"The mechanoreceptor TRPV4 is localized in adherence junctions of the human bladder urothelium: a morphological study","volume":"186","author":"Janssen","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib585","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/GME.0000000000000574","article-title":"Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women\u2014a multicenter, randomized, open-label, controlled comparison study","volume":"23","author":"Jiang","year":"2016","journal-title":"Menopause"},{"key":"10.1124\/pharmrev.121.000523_bib586","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1124\/jpet.116.235846","article-title":"Contribution of GABAA, glycine, and opioid receptors to sacral neuromodulation of nladder overactivity in cats","volume":"359","author":"Jiang","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib587","doi-asserted-by":"crossref","first-page":"F482","DOI":"10.1152\/ajprenal.00586.2016","article-title":"Role of cannabinoid receptor type 1 in tibial and pudendal neuromodulation of bladder overactivity in cats","volume":"312","author":"Jiang","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib588","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/nau.23714","article-title":"Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity","volume":"37","author":"Jiang","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib589","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jamda.2005.04.010","article-title":"Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study","volume":"7","author":"Johnson","year":"2006","journal-title":"J Am Med Dir Assoc"},{"key":"10.1124\/pharmrev.121.000523_bib590","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1476-5381.2009.00317.x","article-title":"Prostanoid receptor antagonists: development strategies and therapeutic applications","volume":"158","author":"Jones","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib591","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00210-008-0365-9","article-title":"Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice","volume":"379","author":"Jositsch","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib592","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2005.04.023","article-title":"Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder","volume":"48","author":"J\u00fcnemann","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib593","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000096338","article-title":"Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder","volume":"77","author":"J\u00fcnemann","year":"2006","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib594","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1139\/cjpp-2015-0091","article-title":"The role of the peripheral cannabinoid system in the pathogenesis of detrusor overactivity evoked by increased intravesical osmolarity in rats","volume":"93","author":"Juszczak","year":"2015","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib595","doi-asserted-by":"crossref","first-page":"F1116","DOI":"10.1152\/ajprenal.00741.2010","article-title":"Gender difference in antidiuretic response to desmopressin","volume":"300","author":"Juul","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib596","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0022-3565(25)13294-1","article-title":"R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine","volume":"247","author":"Kachur","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib597","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0022-5347(05)64634-4","article-title":"Effects of selective \u03b22 and \u03b23-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats","volume":"168","author":"Kaidoh","year":"2002","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib598","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1464-410X.2007.07307.x","article-title":"The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction","volume":"101","author":"Kaiho","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib599","first-page":"351","article-title":"Beta adrenoceptor blockade in the treatment of female urinary stress incontinence","volume":"90","author":"Kaisary","year":"1984","journal-title":"J Urol (Paris)"},{"key":"10.1124\/pharmrev.121.000523_bib600","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.urology.2010.09.036","article-title":"Intravesical electromotive botulinum toxin type A administration: part I\u2014experimental study","volume":"77","author":"Kajbafzadeh","year":"2011","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib601","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.urology.2006.05.056","article-title":"Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele","volume":"68","author":"Kajbafzadeh","year":"2006","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib602","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.urology.2010.03.023","article-title":"Antibody formation following botulinum toxin type A (Dysport) injection in children with intractable bladder hyper-reflexia","volume":"76","author":"Kajbafzadeh","year":"2010","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib603","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12325-020-01517-5","article-title":"Mirabegron add-on therapy to tamsulosin in men with overactive bladder: post hoc analyses of efficacy from the MATCH study","volume":"38","author":"Kakizaki","year":"2021","journal-title":"Adv Ther"},{"key":"10.1124\/pharmrev.121.000523_bib604","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)","volume":"6","author":"Kakizaki","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1124\/pharmrev.121.000523_bib605","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/AOG.0000000000000468","article-title":"Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence","volume":"124","author":"Kalder","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib606","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/bph.12517","article-title":"ADX71441, a novel, potent and selective positive allosteric modulator of the GABA(B) receptor, shows efficacy in rodent models of overactive bladder","volume":"171","author":"Kalinichev","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib607","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eururo.2007.12.029","article-title":"Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity","volume":"54","author":"Kalsi","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib608","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21209","article-title":"Botulinum injections for the treatment of bladder symptoms of multiple sclerosis","volume":"62","author":"Kalsi","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.121.000523_bib609","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2005.11.006","article-title":"Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre","volume":"49","author":"Kalsi","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib610","doi-asserted-by":"crossref","first-page":"15622","DOI":"10.1038\/s41598-018-33967-x","article-title":"Attenuated lipopolysaccharide-induced inflammatory bladder hypersensitivity in mice deficient of transient receptor potential ankilin1","volume":"8","author":"Kamei","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.121.000523_bib611","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.juro.2018.04.050","article-title":"Efficacy and safety of SER120 nasal spray in patients with nocturia: pooled analysis of 2 randomized, double-blind, placebo controlled, phase 3 trials","volume":"200","author":"Kaminetsky","year":"2018","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib612","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/B978-0-12-820683-6.00021-X","article-title":"Nocturnal enuresis in children: the role of arginine-vasopressin","volume":"181","author":"Kamperis","year":"2021","journal-title":"Handb Clin Neurol"},{"key":"10.1124\/pharmrev.121.000523_bib613","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11255-011-9979-9","article-title":"Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity","volume":"44","author":"Kanagarajah","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib614","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.juro.2009.12.060","article-title":"Bladder afferent signaling: recent findings","volume":"183","author":"Kanai","year":"2010","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib615","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/00498250601140072","article-title":"Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes","volume":"37","author":"Kanayama","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/pharmrev.121.000523_bib616","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1476-5381.2008.00099.x","article-title":"Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1\/2","volume":"156","author":"Kang","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib617","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2012.07.003","article-title":"Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial","volume":"63","author":"Kaplan","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib618","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","article-title":"Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS)","volume":"203","author":"Kaplan","year":"2020","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib619","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib620","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","article-title":"Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score","volume":"102","author":"Kaplan","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib621","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.121.000523_bib622","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/ijcp.12360","article-title":"Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure","volume":"68","author":"Karsenty","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib623","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","article-title":"Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux","volume":"177","author":"Karsenty","year":"2007","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib624","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0024-3205(02)01848-9","article-title":"Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats","volume":"71","author":"Katofiasc","year":"2002","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000523_bib625","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1177\/1352458510378020","article-title":"Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis","volume":"16","author":"Kavia","year":"2010","journal-title":"Mult Scler"},{"key":"10.1124\/pharmrev.121.000523_bib626","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clinthera.2005.01.006","article-title":"Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly","volume":"27","author":"Kay","year":"2005","journal-title":"Clin Ther"},{"key":"10.1124\/pharmrev.121.000523_bib627","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1471-0528.1997.tb12055.x","article-title":"Analysis of collagen status in premenopausal nulliparous women with genuine stress incontinence","volume":"104","author":"Keane","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1124\/pharmrev.121.000523_bib628","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1464-410X.2004.05255.x","article-title":"Improved quality of life in patients with overactive bladder symptoms treated with solifenacin","volume":"95","author":"Kelleher","year":"2005","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib629","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1464-410X.2011.10774.x","article-title":"Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies","volume":"110","author":"Kelleher","year":"2012","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib630","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1464-410X.2008.07710.x","article-title":"Impact of fesoterodine on quality of life: pooled data from two randomized trials","volume":"102","author":"Kelleher","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib631","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1523\/JNEUROSCI.3115-06.2007","article-title":"Identification of atropine- and P2X1 receptor antagonist-resistant, neurogenic contractions of the urinary bladder","volume":"27","author":"Kennedy","year":"2007","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib632","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2022.03.010","article-title":"Efficacy and safety of abobotulinumtoxinA in patients with neurogenic detrusor overactivity incontinence performing regular clean intermittent catherization: pooled results from two phase III randomized studies (CONTENT1 and CONTENT2)","volume":"82","author":"Kennelly","year":"2022","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib633","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","article-title":"Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis","volume":"81","author":"Kennelly","year":"2013","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib634","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/nau.22934","article-title":"Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study","volume":"36","author":"Kennelly","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib635","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1080\/03007995.2018.1443061","article-title":"Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings","volume":"34","author":"Kennelly","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pharmrev.121.000523_bib636","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1021\/acschemneuro.0c00254","article-title":"Classics in chemical neuroscience: baclofen","volume":"11","author":"Kent","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib637","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","article-title":"Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase","volume":"375","author":"Kerbrat","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000523_bib638","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2125.2003.01967.x","article-title":"Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability","volume":"56","author":"Kerbusch","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib639","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1056\/NEJM200012213432501","article-title":"Phenylpropanolamine and the risk of hemorrhagic stroke","volume":"343","author":"Kernan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000523_bib640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016718","article-title":"Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach","volume":"6","author":"Kessler","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib641","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2009.09.023","article-title":"In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results","volume":"57","author":"Kessler","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib642","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.juro.2010.12.002","article-title":"Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis","volume":"185","author":"Khan","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib643","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11884-019-00503-0","article-title":"Functional brain imaging in voiding dysfunction","volume":"14","author":"Khavari","year":"2019","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"10.1124\/pharmrev.121.000523_bib644","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.neuint.2004.06.001","article-title":"Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury","volume":"45","author":"Khera","year":"2004","journal-title":"Neurochem Int"},{"key":"10.1124\/pharmrev.121.000523_bib645","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib646","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00192-011-1522-0","article-title":"Time-to-effect with darifenacin in overactive bladder: a pooled analysis","volume":"22","author":"Khullar","year":"2011","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib647","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urology.2007.12.017","article-title":"Fesoterodine dose response in subjects with overactive bladder syndrome","volume":"71","author":"Khullar","year":"2008","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib648","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.archger.2016.03.019","article-title":"Hypovitaminosis D is an independent associated factor of overactive bladder in older adults","volume":"65","author":"Kilic","year":"2016","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1124\/pharmrev.121.000523_bib649","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5213\/inj.1836188.094","article-title":"Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis","volume":"23","author":"Kim","year":"2019","journal-title":"Int Neurourol J"},{"key":"10.1124\/pharmrev.121.000523_bib650","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5213\/inj.1630492.246","article-title":"17Beta-estradiol inhibits calcium-activated potassium channel expressions in rat whole bladder","volume":"20","author":"Kim","year":"2016","journal-title":"Int Neurourol J"},{"key":"10.1124\/pharmrev.121.000523_bib651","article-title":"Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib652","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pros.10277","article-title":"Adrenergic regulation of the intracellular [Ca2+] and voltage-operated Ca2+ channel currents in the rat prostate neuroendocrine cells","volume":"57","author":"Kim","year":"2003","journal-title":"Prostate"},{"key":"10.1124\/pharmrev.121.000523_bib653","doi-asserted-by":"crossref","first-page":"747","DOI":"10.12965\/jer.1938744.372","article-title":"Basic neurourology","volume":"15","author":"Kim","year":"2019","journal-title":"J Exerc Rehabil"},{"key":"10.1124\/pharmrev.121.000523_bib654","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12894-017-0313-4","article-title":"Expression of cannabinoid 1 and, 2 receptors and the effects of cannabinoid 1 and, 2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib655","doi-asserted-by":"crossref","first-page":"17511","DOI":"10.3390\/ijms140917511","article-title":"Functional and molecular changes of the bladder in rats with crushing injury of nerve bundles from major pelvic ganglion to the bladder: role of RhoA\/Rho kinase pathway","volume":"14","author":"Kim","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.121.000523_bib656","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bju.13267","article-title":"Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an \u03b1-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial","volume":"117","author":"Kim","year":"2016","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib657","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4111\/icu.2016.57.2.84","article-title":"Persistence and compliance with medication management in the treatment of overactive bladder","volume":"57","author":"Kim","year":"2016","journal-title":"Investig Clin Urol"},{"key":"10.1124\/pharmrev.121.000523_bib658","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2016.1174680","article-title":"Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea","volume":"32","author":"Kim","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pharmrev.121.000523_bib659","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.urology.2004.11.021","article-title":"Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways","volume":"65","author":"Kim","year":"2005","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib660","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0024-3205(92)90374-X","article-title":"\u03b2-Adrenergic agonists and hypertrophy of skeletal muscles","volume":"50","author":"Kim","year":"1992","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000523_bib661","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0302-2838(03)00141-6","article-title":"Snoring as a cause of nocturia in men with lower urinary tract symptoms","volume":"43","author":"Kinn","year":"2003","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib662","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib663","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/aps.2013.126","article-title":"Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro","volume":"35","author":"Kirschstein","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/pharmrev.121.000523_bib664","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12894-015-0098-2","article-title":"Inverse relationship of Rho kinase and myosin-light chain kinase expression in the aging human detrusor smooth muscle","volume":"15","author":"Kirschstein","year":"2015","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib665","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1620\/tjem.165.243","article-title":"Effect of clenbuterol on contractile response in periurethral striated muscle of rabbits","volume":"165","author":"Kishimoto","year":"1991","journal-title":"Tohoku J Exp Med"},{"key":"10.1124\/pharmrev.121.000523_bib666","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2009.01.034","article-title":"Potentiation of carbachol-induced detrusor smooth muscle contractions by \u03b2-adrenoceptor activation","volume":"606","author":"Klausner","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib667","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/nau.24537","article-title":"A retrospective review of the long term clinical outcomes of patients with neurogenic lower urinary tract dysfunction following transverse myelitis","volume":"40","author":"Knight","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib668","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2008.07.015","article-title":"Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis","volume":"61","author":"Kobata","year":"2008","journal-title":"Maturitas"},{"key":"10.1124\/pharmrev.121.000523_bib669","first-page":"147","article-title":"Pharmacological effects of imidafenacin (KRP-197\/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task","volume":"57","author":"Kobayashi","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/pharmrev.121.000523_bib670","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/pros.21003","article-title":"Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia","volume":"69","author":"Kojima","year":"2009","journal-title":"Prostate"},{"key":"10.1124\/pharmrev.121.000523_bib671","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00210-003-0713-8","article-title":"Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3 receptors?","volume":"367","author":"Kories","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib672","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/nau.23955","article-title":"Effect of imipramine on urethral opening pressure: A randomized, double-blind, placebo-controlled crossover study in healthy women","volume":"38","author":"Kornholt","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib673","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/13685538.2014.951922","article-title":"Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin","volume":"18","author":"Kosilov","year":"2015","journal-title":"Aging Male"},{"key":"10.1124\/pharmrev.121.000523_bib674","first-page":"43","article-title":"Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy","volume":"67","author":"Kosilov","year":"2014","journal-title":"Cent European J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib675","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1756287214544896","article-title":"Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance","volume":"6","author":"Kosilov","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1124\/pharmrev.121.000523_bib676","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1557988315595692","article-title":"Effectiveness of solifenacin and trospium for managing of severe symptoms of overactive bladder in patients with benign prostatic hyperplasia","volume":"10","author":"Kosilov","year":"2016","journal-title":"Am J Men Health"},{"key":"10.1124\/pharmrev.121.000523_bib677","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.euf.2020.06.007","article-title":"Use of duloxetine for postprostatectomy stress urinary incontinence: a systematic review","volume":"7","author":"Kotecha","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1124\/pharmrev.121.000523_bib678","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.urology.2010.03.097","article-title":"Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder","volume":"76","author":"Kraus","year":"2010","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib679","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.juro.2013.05.011","article-title":"Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study","volume":"190","author":"Krause","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib680","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","article-title":"Pharmacokinetic properties of mirabegron, a \u03b23-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women","volume":"34","author":"Krauwinkel","year":"2012","journal-title":"Clin Ther"},{"key":"10.1124\/pharmrev.121.000523_bib681","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00345-020-03211-1","article-title":"Are 200 units of onabotulinumtoxin A sufficient for the suppression of neurogenic detrusor overactivity in individuals with established 300-unit botulinum toxin treatment? A retrospective cohort study","volume":"39","author":"Krebs","year":"2021","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib682","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/nau.23566","article-title":"Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study","volume":"37","author":"Krhut","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib683","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00210-018-1542-0","article-title":"Involvement of TRPM4 in detrusor overactivity following spinal cord transection in mice","volume":"391","author":"Kullmann","year":"2018","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib684","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/nau.24183","article-title":"Initial report on distribution of \u03b23-adrenoceptor in the human female urethra","volume":"39","author":"Kummeling","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib685","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coph.2014.03.001","article-title":"Non-neuronal cholinergic airway epithelium biology","volume":"16","author":"Kummer","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib686","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1464-410X.2003.04441.x","article-title":"Effectiveness of intravesical resiniferatoxin in treating detrusor hyper-reflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions","volume":"92","author":"Kuo","year":"2003","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib687","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2003.12.007","article-title":"Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents","volume":"63","author":"Kuo","year":"2004","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib688","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1464-410X.2005.05458.x","article-title":"Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics","volume":"95","author":"Kuo","year":"2005","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib689","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib690","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib691","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.juro.2006.03.087","article-title":"Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study","volume":"176","author":"Kuo","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib692","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.juro.2010.09.108","article-title":"Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey","volume":"185","author":"Kupelian","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib693","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2011.05.065","article-title":"Nocturia and quality of life: results from the Boston area community health survey","volume":"61","author":"Kupelian","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib694","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12894-016-0127-9","article-title":"Uni-axial stretch induces actin stress fiber reorganization and activates c-Jun NH2 terminal kinase via RhoA and Rho kinase in human bladder smooth muscle cells","volume":"16","author":"Kushida","year":"2016","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib695","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00210-009-0462-4","article-title":"Apoptosis induction by doxazosin and other quinazoline \u03b11-adrenoceptor antagonists: a new mechanism for cancer treatment?","volume":"380","author":"Kyprianou","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib696","first-page":"3","article-title":"Sexual dysfunction related to drugs: a critical review. Part V: \u03b1-blocker and 5-ARI drugs","volume":"49","author":"La Torre","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"10.1124\/pharmrev.121.000523_bib697","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17512433.2018.1411801","article-title":"Pharmacological treatments available for the management of underactive bladder in neurological conditions","volume":"11","author":"Ladi-Seyedian","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib698","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.urology.2020.04.104","article-title":"Botulinum toxin type A therapy: intravesical injection or electromotive drug administration","volume":"142","author":"Ladi-Seyedian","year":"2020","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib699","doi-asserted-by":"crossref","first-page":"F803","DOI":"10.1152\/ajprenal.90269.2008","article-title":"AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome","volume":"295","author":"Lashinger","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib700","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-5347(05)67279-5","article-title":"Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study","volume":"164","author":"Lazzeri","year":"2000","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib701","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0022-5347(01)68164-3","article-title":"Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor","volume":"158","author":"Lazzeri","year":"1997","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib702","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0302-2838(03)00418-4","article-title":"Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study","volume":"45","author":"Lazzeri","year":"2004","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib703","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/003655998750015287","article-title":"Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases","volume":"32","author":"Lazzeri","year":"1998","journal-title":"Scand J Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib704","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(01)00285-3","article-title":"Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system","volume":"101","author":"Lecci","year":"2001","journal-title":"Regul Pept"},{"key":"10.1124\/pharmrev.121.000523_bib705","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40261-013-0084-y","article-title":"Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a \u03b23-adrenoceptor agonist","volume":"33","author":"Lee","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1124\/pharmrev.121.000523_bib706","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/01.ju.0000173630.94559.fd","volume":"174","author":"Lee","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib707","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/ijcp.12272","article-title":"A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder","volume":"67","author":"Lee","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib708","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/luts.12124","article-title":"Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study","volume":"9","author":"Lee","year":"2017","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib709","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1038\/s41598-021-87505-3","article-title":"Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS\/PI3K\/AKT\/eNOS pathway in fructose-fed rats","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.121.000523_bib710","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1742-1241.2011.02728.x","article-title":"Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial","volume":"65","author":"Lee","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib711","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/nau.22325","article-title":"Functional roles of transient receptor potential melastatin 8 (TRPM8) channels in the cold stress-induced detrusor overactivity pathways in conscious rats","volume":"32","author":"Lei","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib712","doi-asserted-by":"crossref","first-page":"33197","DOI":"10.1038\/srep33197","article-title":"Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity","volume":"6","author":"Leitner","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.121.000523_bib713","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bju.13500","article-title":"Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder","volume":"119","author":"Leng","year":"2017","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib714","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12894-019-0495-z","article-title":"Expression of components of the urothelial cholinergic system in bladder and cultivated primary urothelial cells of the pig","volume":"19","author":"Leonh\u00e4user","year":"2019","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib715","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia","volume":"335","author":"Lepor","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000523_bib716","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","volume":"2016","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib717","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.bjp.0707455","article-title":"Store-operated calcium entry in vascular smooth muscle","volume":"153","author":"Leung","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib718","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1111\/bph.15172","article-title":"Regulation of smooth muscle contraction by monomeric non-RhoA GTPases","volume":"177","author":"Li","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib719","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00210-019-01797-x","article-title":"The STK16 inhibitor STK16-IN-1 inhibits non-adrenergic and non-neurogenic smooth muscle contractions in the human prostate and the human male detrusor","volume":"393","author":"Li","year":"2020","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2018.02.016","article-title":"The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice","volume":"329","author":"Li","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1124\/pharmrev.121.000523_bib721","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib722","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/nau.23187","article-title":"Involvement of opioid receptors in inhibition of bladder overactivity induced by sacral neuromodulation in pigs: a possible action mechanism","volume":"36","author":"Li","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib723","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib724","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/SPV.0000000000000496","article-title":"Real-world retention rates after intravesical onabotulinumtoxinA for idiopathic overactive bladder","volume":"24","author":"Liberman","year":"2018","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1124\/pharmrev.121.000523_bib725","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00441-010-1053-x","article-title":"\u03b2-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder","volume":"342","author":"Limberg","year":"2010","journal-title":"Cell Tissue Res"},{"key":"10.1124\/pharmrev.121.000523_bib726","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1471-0528.1999.tb08119.x","article-title":"Comparison of treatment outcomes for imipramine for female genuine stress incontinence","volume":"106","author":"Lin","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1124\/pharmrev.121.000523_bib727","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.urology.2013.09.036","article-title":"Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men\u2014a randomized multicenter study","volume":"83","author":"Lin","year":"2014","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib728","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ejphar.2018.06.018","article-title":"Effect of co-administration of two different phosphodiesterase inhibitors and a \u03b23-adrenoceptor agonist in an experimental model of detrusor overactivity","volume":"833","author":"Linhares","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib729","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s10753-018-0888-2","article-title":"The effects of neurokinin-1 receptor antagonist in an experimental autoimmune cystitis model resembling bladder pain syndrome\/interstitial cystitis","volume":"42","author":"Liu","year":"2019","journal-title":"Inflammation"},{"key":"10.1124\/pharmrev.121.000523_bib730","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.eururo.2008.04.037","article-title":"Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection","volume":"56","author":"Liu","year":"2009","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib731","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1464-410X.2007.07151.x","article-title":"Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity","volume":"100","author":"Liu","year":"2007","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib732","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/nau.20326","article-title":"The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder","volume":"26","author":"Liu","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib733","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/sj.bjp.0701328","article-title":"The role of cyclic nucleotides in guinea-pig bladder contractility","volume":"121","author":"Longhurst","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib734","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1097\/01.ju.0000085667.05190.ad","article-title":"Trospium chloride for the treatment of detrusor instability in children","volume":"170","author":"Lopez Pereira","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib735","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/01.ju.0000136203.76320.f6","article-title":"Clinical experiences with desmopressin for long-term treatment of nocturia","volume":"172","author":"Lose","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib736","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1464-410x.2001.02227.x","article-title":"Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor","volume":"87","author":"Lose","year":"2001","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib737","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autneu.2016.02.001","article-title":"Central control of visceral pain and urinary tract function","volume":"200","author":"Lovick","year":"2016","journal-title":"Auton Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib738","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/nau.23256","article-title":"Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents","volume":"36","author":"Lua","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib739","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1464-410X.2007.07312.x","article-title":"Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation","volume":"101","author":"Lucioni","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib740","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1419520","article-title":"Defining the efficacy and safety of phosphodiesterase type 5 inhibitors with tamsulosin for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia with or without erectile dysfunction: a network meta-analysis","volume":"2020","author":"Ma","year":"2020","journal-title":"BioMed Res Int"},{"key":"10.1124\/pharmrev.121.000523_bib741","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.juro.2016.03.174","article-title":"Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacin monotherapy: responder analyses and patient-reported outcomes from the BESIDE study. corrected","volume":"196","author":"MacDiarmid","year":"2016","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib742","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1464-410x.1999.00251.x","article-title":"A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence","volume":"84","author":"Madersbacher","year":"1999","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib743","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s003450100223","article-title":"Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic)","volume":"19","author":"Madersbacher","year":"2001","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib744","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","article-title":"Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia","volume":"75","author":"Madersbacher","year":"1995","journal-title":"Br J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib745","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","article-title":"Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis","volume":"62","author":"Madhuvrata","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib746","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.urology.2015.01.028","article-title":"Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia","volume":"85","author":"Maeda","year":"2015","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib747","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0022-3565(25)23645-X","article-title":"Effect of acute or chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats","volume":"248","author":"Maggi","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib748","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bju.13025","article-title":"Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder","volume":"116","author":"Malde","year":"2015","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib749","doi-asserted-by":"crossref","first-page":"556","DOI":"10.5414\/CPP46556","article-title":"Pharmacokinetic profile of fesoterodine","volume":"46","author":"Malhotra","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000523_bib750","first-page":"999","article-title":"Pharmacokinetic profile of fesoterodine, a novel antimuscarinic treatment for overactive bladder","volume":"65","author":"Malhotra","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib751","doi-asserted-by":"crossref","first-page":"F257","DOI":"10.1152\/ajprenal.00048.2020","article-title":"Urinary bladder smooth muscle ion channels: expression, function, and regulation in health and disease","volume":"319","author":"Malysz","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib752","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.121.000523_bib753","first-page":"S50","article-title":"Is coexistent overactive-underactive bladder (with or without detrusor overactivity and underactivity) a real clinical syndrome? ICI-RS 2019","volume":"39","author":"Mancini","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib754","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","article-title":"Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity","volume":"61","author":"Manecksha","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib755","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib756","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","volume":"65","author":"Mangera","year":"2014","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib757","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10072-017-3148-6","article-title":"THC\/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study","volume":"39","author":"Maniscalco","year":"2018","journal-title":"Neurol Sci"},{"key":"10.1124\/pharmrev.121.000523_bib758","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bjp.0706147","article-title":"Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing","volume":"144","author":"Mansfield","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib759","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00345-016-1862-y","article-title":"Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms","volume":"35","author":"Marcelissen","year":"2017","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib760","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/nau.20928","article-title":"Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder","volume":"30","author":"Marencak","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib761","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eururo.2006.08.041","article-title":"Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review","volume":"51","author":"Mariappan","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib762","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults","volume":"3","author":"Mariappan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib763","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/jgs.15711","article-title":"Comparing vitamin D supplementation versus placebo for urgency urinary incontinence: a pilot study","volume":"67","author":"Markland","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1124\/pharmrev.121.000523_bib764","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2008.04.062","article-title":"Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial","volume":"55","author":"Marschall-Kehrel","year":"2009","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib765","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0029-1246193","article-title":"Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children","volume":"20","author":"Marte","year":"2010","journal-title":"Eur J Pediatr Surg"},{"key":"10.1124\/pharmrev.121.000523_bib766","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2019.12.001","article-title":"Onabotulinumtoxina re-injection for refractory detrusor overactivity using 3-4 injection sites: results of a pilot study","volume":"137","author":"Mart\u00ednez-Cuenca","year":"2020","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib767","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2008.04.027","article-title":"Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study","volume":"56","author":"Mart\u00ednez-Garc\u00eda","year":"2009","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib768","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5152\/tud.2020.19259","article-title":"Refractory bladder dysfunction: a multi-institutional experience with intravesical botulinum toxin-a injection in adult patients who underwent previous augmentation cystoplasty","volume":"46","author":"Martinez","year":"2020","journal-title":"Turk J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib769","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00210-012-0755-x","article-title":"Bladder selectivity of ritobegron (KUC-7483), a novel \u03b23-adrenoceptor agonist: on the in vitro and in vivo studies","volume":"385","author":"Maruyama","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib770","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1442-2042.2006.01538.x","article-title":"Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study","volume":"13","author":"Maruyama","year":"2006","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib771","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/nau.20515","article-title":"Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients","volume":"27","author":"Mascarenhas","year":"2008","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib772","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejogrb.2018.01.002","article-title":"Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?","volume":"222","author":"Matarazzo","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1124\/pharmrev.121.000523_bib773","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JU.0000000000000525","article-title":"Treatment response and complications after intradetrusor onabotulinumtoxinA injection in male patients with idiopathic overactive bladder syndrome","volume":"203","author":"Mateu Arrom","year":"2020","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib774","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/978-3-642-54215-2_18","article-title":"TRPM4","volume":"222","author":"Mathar","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib775","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1124\/jpet.102.044701","article-title":"Increased relaxant action of forskolin and isoproterenol against muscarinic agonist-induced contractions in smooth muscle from M2 receptor knockout mice","volume":"305","author":"Matsui","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib776","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1523\/JNEUROSCI.22-24-10627.2002","article-title":"Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable","volume":"22","author":"Matsui","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib777","doi-asserted-by":"crossref","first-page":"9579","DOI":"10.1073\/pnas.97.17.9579","article-title":"Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M 3 subtype","volume":"97","author":"Matsui","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/pharmrev.121.000523_bib778","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000502661","article-title":"What are factors contributing to improvement of overactive bladder symptoms after alpha-1 blocker treatment in patients with both storage and voiding symptoms?","volume":"103","author":"Matsukawa","year":"2019","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib779","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/nau.23013","volume":"36","author":"Matsukawa","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib780","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1442-2042.2003.00637.x","article-title":"Bladder smooth muscle cell phenotypic changes and implication of expression of contractile proteins (especially caldesmon) in rats after partial outlet obstruction","volume":"10","author":"Matsumoto","year":"2003","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib781","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2008.08185.x","article-title":"Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model","volume":"103","author":"Matsumoto","year":"2009","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib782","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/luts.12283","article-title":"Efficacy of tadalafil therapy and changes in oxidative stress levels in male patients with lower urinary tract symptoms and overactive bladder","volume":"12","author":"Matsuo","year":"2020","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib783","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0022-5347(01)65572-1","article-title":"Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms","volume":"156","author":"Matthiesen","year":"1996","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib784","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1464-410X.2002.02791.x","article-title":"Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men","volume":"89","author":"Mattiasson","year":"2002","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib785","doi-asserted-by":"crossref","first-page":"E194","DOI":"10.1503\/cmaj.151104","article-title":"Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports","volume":"189","author":"Maund","year":"2017","journal-title":"CMAJ"},{"key":"10.1124\/pharmrev.121.000523_bib786","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/aogs.12196","article-title":"Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database","volume":"92","author":"Mauseth","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1124\/pharmrev.121.000523_bib787","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0091270008315314","article-title":"Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms","volume":"48","author":"May","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib788","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/00365599509180578","article-title":"Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. a multicentre dose-optimizing study","volume":"29","author":"Mazur","year":"1995","journal-title":"Scand J Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib789","doi-asserted-by":"crossref","first-page":"F507","DOI":"10.1152\/ajprenal.00054.2008","article-title":"Enhanced bladder capacity and reduced prostaglandin E2-mediated bladder hyperactivity in EP3 receptor knockout mice","volume":"295","author":"McCafferty","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib790","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000523_bib791","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00383-011-3039-5","article-title":"Urinary incontinence in children: botulinum toxin is a safe and effective treatment option","volume":"28","author":"McDowell","year":"2012","journal-title":"Pediatr Surg Int"},{"key":"10.1124\/pharmrev.121.000523_bib792","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40261-012-0046-9","article-title":"Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms","volume":"33","author":"McKeage","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1124\/pharmrev.121.000523_bib793","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib794","first-page":"343","article-title":"Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding\/over active bladder: a systematic review","volume":"57","author":"Medhi","year":"2013","journal-title":"Indian J Physiol Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib795","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.juro.2010.05.035","article-title":"The effect of botulinum toxin type A on overactive bladder symptoms in patients with multiple sclerosis: a pilot study","volume":"184","author":"Mehnert","year":"2010","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib796","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00345-008-0362-0","article-title":"A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging","volume":"27","author":"Mehnert","year":"2009","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib797","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.neuroimage.2008.03.006","article-title":"Brain activation in response to bladder filling and simultaneous stimulation of the dorsal clitoral nerve--an fMRI study in healthy women","volume":"41","author":"Mehnert","year":"2008","journal-title":"Neuroimage"},{"key":"10.1124\/pharmrev.121.000523_bib798","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","article-title":"Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential","volume":"120","author":"Meng","year":"2007","journal-title":"J Cell Sci"},{"key":"10.1124\/pharmrev.121.000523_bib799","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2006.10.055","article-title":"Vattikuti Institute prostatectomy: contemporary technique and analysis of results","volume":"51","author":"Menon","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib800","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neulet.2008.08.076","article-title":"Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats","volume":"445","author":"Merriam","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.121.000523_bib801","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2165\/00002018-200225120-00004","article-title":"A benefit-risk assessment of extended-release oxybutynin","volume":"25","author":"Michel","year":"2002","journal-title":"Drug Saf"},{"key":"10.1124\/pharmrev.121.000523_bib802","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1742-1241.2007.01363.x","article-title":"Duloxetine\u2014three birds with one stone?","volume":"61","author":"Michel","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib803","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.9.10.1787","article-title":"Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome","volume":"9","author":"Michel","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pharmrev.121.000523_bib804","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev-pharmtox-010814-124536","article-title":"Therapeutic modulation of urinary bladder function: multiple targets at multiple levels","volume":"55","author":"Michel","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.121.000523_bib805","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bph.13379","article-title":"How \u03b23 -adrenoceptor-selective is mirabegron?","volume":"173","author":"Michel","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib806","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/iju.14189","article-title":"Where will the next generation of medical treatments for overactive bladder syndrome come from?","volume":"27","author":"Michel","year":"2020","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib807","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pharmthera.2007.12.001","article-title":"Physiological and pathological regulation of the autonomic control of urinary bladder contractility","volume":"117","author":"Michel","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000523_bib808","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00210-015-1137-y","article-title":"Are blood vessels a target to treat lower urinary tract dysfunction?","volume":"388","author":"Michel","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000523_bib809","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1464-410X.2005.05651.x","article-title":"Role of muscarinic receptor antagonists in urgency and nocturia","volume":"96","author":"Michel","year":"2005","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib810","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2004.11.012","article-title":"Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder","volume":"48","author":"Michel","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib811","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/14740338.2016.1160055","article-title":"Safety and tolerability of \u03b23-adrenoceptor agonists in the treatment of overactive bladder syndrome\u2014insight from transcriptosome and experimental studies","volume":"15","author":"Michel","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1124\/pharmrev.121.000523_bib812","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00210-006-0105-y","article-title":"Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?","volume":"374","author":"Michel","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib813","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14728222.2015.1009447","article-title":"Therapeutic targets for overactive bladder other than smooth muscle","volume":"19","author":"Michel","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1124\/pharmrev.121.000523_bib814","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pharmthera.2016.01.007","article-title":"\u03b23-Adrenoceptor agonists for overactive bladder syndrome: role of translational pharmacology in a repositioning clinical drug development project","volume":"159","author":"Michel","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000523_bib815","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2125.2012.04389.x","article-title":"Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice","volume":"75","author":"Michel","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib816","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.119.118927","article-title":"New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology","volume":"97","author":"Michel","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib817","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eursup.2004.10.004","article-title":"The neuro-urological connection","volume":"4","author":"Michel","year":"2005","journal-title":"Eur Urol Suppl"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000523_bib818","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1464-410X.2004.04811.x","article-title":"Role of serotonin and noradrenaline in stress urinary incontinence","volume":"94","author":"Michel","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib819","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2125.2011.04138.x","article-title":"Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years","volume":"73","author":"Michel","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib820","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00345-009-0416-y","article-title":"Effect of pre-contraction on \u03b2-adrenoceptor-mediated relaxation of rat urinary bladder","volume":"27","author":"Michel","year":"2009","journal-title":"World J Urol"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.121.000523_bib821","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1464-410X.2000.00094.x","article-title":"\u03b1-Blockers and lower urinary tract function: more than smooth muscle relaxation?","volume":"86","author":"Michel","year":"2000","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib822","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0022-5347(05)64567-3","article-title":"Does gender or age affect the efficacy and safety of tolterodine?","volume":"168","author":"Michel","year":"2002","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib823","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3389\/fphar.2020.00816","article-title":"Factors associated with nocturia-related quality of life in men with lower urinary tract symptoms and treated with tamsulosin oral controlled absorption system in a non-interventional study","volume":"11","author":"Michel","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib824","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/biomedicines10020270","article-title":"Study designs for evaluation of combination treatment: focus on individual patient benefit","volume":"10","author":"Michel","year":"2022","journal-title":"Biomedicines"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.121.000523_bib825","first-page":"S88","article-title":"\u03b11-, \u03b12- and \u03b2-adrenoceptors in the urinary bladder, urethra and prostate","volume":"147","author":"Michel","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"Suppl 4","key":"10.1124\/pharmrev.121.000523_bib826","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1464-410X.2005.05485.x","article-title":"Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on \u03b1-adrenoceptor antagonists","volume":"95","author":"Milani","year":"2005","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib827","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1464-410X.2004.04607.x","article-title":"Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial","volume":"93","author":"Millard","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib828","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00210-015-1167-5","article-title":"What is the main mechanism of tramadol?","volume":"388","author":"Minami","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib829","doi-asserted-by":"crossref","first-page":"R629","DOI":"10.1152\/ajpregu.00013.2015","article-title":"Social stress in mice induces urinary bladder overactivity and increases TRPV1 channel-dependent afferent nerve activity","volume":"309","author":"Mingin","year":"2015","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib830","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/nau.23148","article-title":"Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB","volume":"36","author":"Miotla","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib831","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","article-title":"Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial","volume":"75","author":"Mitcheson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib832","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0302-2838(02)00041-6","article-title":"Symptomatic benign prostate hyperplasia: impact on partners\u2019 quality of life","volume":"41","author":"Mitropoulos","year":"2002","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib833","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.juro.2007.10.030","article-title":"GABA receptor activation in the lumbosacral spinal cord decreases detrusor overactivity in spinal cord injured rats","volume":"179","author":"Miyazato","year":"2008","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib834","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/bph.13897","article-title":"The \u03b23 -adrenoceptor agonist mirabegron increases human atrial force through \u03b21 -adrenoceptors: an indirect mechanism?","volume":"174","author":"Mo","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib835","doi-asserted-by":"crossref","first-page":"21257","DOI":"10.1074\/jbc.M109.020206","article-title":"The TRPV4 cation channel mediates stretch-evoked Ca2+ influx and ATP release in primary urothelial cell cultures","volume":"284","author":"Mochizuki","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.121.000523_bib836","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001405","article-title":"Oestrogens for urinary incontinence in women","volume":"2","author":"Moehrer","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib837","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib838","doi-asserted-by":"crossref","first-page":"F537","DOI":"10.1152\/ajprenal.00400.2020","article-title":"Isoprostanes evoke contraction of the murine and human detrusor muscle via activation of the thromboxane prostanoid TP receptor and Rho kinase","volume":"320","author":"Moln\u00e1r","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib839","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrurol.2017.181","article-title":"Stimulators and activators of soluble guanylate cyclase for urogenital disorders","volume":"15","author":"M\u00f3nica","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1124\/pharmrev.121.000523_bib840","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14656566.2019.1589452","article-title":"Tadalafil for the treatment of benign prostatic hyperplasia","volume":"20","author":"M\u00f3nica","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pharmrev.121.000523_bib841","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/toxins8040088","article-title":"Use of botulinum toxin A in the treatment of lower urinary tract disorders: a review of the literature","volume":"8","author":"Moore","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1124\/pharmrev.121.000523_bib842","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001813-200409000-00003","article-title":"Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients","volume":"15","author":"Morales","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib843","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1743-6109.2009.01558.x","article-title":"Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats","volume":"7","author":"Morelli","year":"2010","journal-title":"J Sex Med"},{"key":"10.1124\/pharmrev.121.000523_bib844","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1743-6109.2009.01249.x","article-title":"Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA\/Rho kinase signaling pathway in spontaneously hypertensive rats","volume":"6","author":"Morelli","year":"2009","journal-title":"J Sex Med"},{"key":"10.1124\/pharmrev.121.000523_bib845","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1111\/j.1743-6109.2011.02416.x","article-title":"Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats","volume":"8","author":"Morelli","year":"2011","journal-title":"J Sex Med"},{"key":"10.1124\/pharmrev.121.000523_bib846","doi-asserted-by":"crossref","first-page":"C1206","DOI":"10.1152\/ajpcell.90634.2007","article-title":"The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder","volume":"294","author":"Morelli","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib847","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/pros.20463","article-title":"BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA\/Rho kinase signaling in rat and human bladder","volume":"67","author":"Morelli","year":"2007","journal-title":"Prostate"},{"key":"10.1124\/pharmrev.121.000523_bib848","doi-asserted-by":"crossref","first-page":"25665","DOI":"10.1074\/jbc.M311515200","article-title":"Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity","volume":"279","author":"Morenilla-Palao","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.121.000523_bib849","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000282608","article-title":"Effects of prostaglandins E1, E2 and F2 alpha on contractility and cAMP and cGMP contents in lower urinary tract smooth muscle","volume":"52","author":"Morita","year":"1994","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib850","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/nau.24839","article-title":"The effectiveness of parasympathomimetics for treating underactive bladder: a systematic review and meta-analysis","volume":"41","author":"Moro","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib851","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14740338.2019.1652269","article-title":"Cognitive and mood side effects of lower urinary tract medication","volume":"18","author":"M\u00fcderrisoglu","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1124\/pharmrev.121.000523_bib852","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s12325-022-02114-4","article-title":"What are realistic expectations to become free of overactive bladder symptoms? Experience from non-interventional studies with propiverine","volume":"39","author":"M\u00fcderrisoglu","year":"2022","journal-title":"Adv Ther"},{"key":"10.1124\/pharmrev.121.000523_bib853","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2490-6-6","article-title":"Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations","volume":"6","author":"Mukerji","year":"2006","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib854","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000072681","article-title":"Pharmacological effects of KRP-197 on the human isolated urinary bladder","volume":"71","author":"Murakami","year":"2003","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib855","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1464-410X.2004.04560.x","article-title":"A randomized crossover study to evaluate Ro 115-1240, a selective \u03b11A\/1L-adrenoceptor partial agonist in women with stress urinary incontinence","volume":"93","author":"Musselman","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib856","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.juro.2008.11.077","article-title":"Biochemical alterations in partial bladder outlet obstruction in mice: up-regulation of the mitogen activated protein kinase pathway","volume":"181","author":"Myers","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib857","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5489\/cuaj.1356","article-title":"Long-term use of solifenacin in pediatric patients with overactive bladder: extension of a prospective open-label study","volume":"8","author":"Nadeau","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1124\/pharmrev.121.000523_bib858","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/2090598X.2019.1605676","article-title":"Delivery of intravesical botulinum toxin A using low-energy shockwaves in the treatment of overactive bladder: a preliminary clinical study","volume":"17","author":"Nageib","year":"2019","journal-title":"Arab J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib859","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0022-5347(01)69090-6","article-title":"A randomized, double-blind, placebo controlled crossover trial of nimodipine in older persons with detrusor instability and urge incontinence","volume":"167","author":"Naglie","year":"2002","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib860","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.juro.2010.05.093","article-title":"Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study","volume":"184","author":"Nakagawa","year":"2010","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib861","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.119.263616","article-title":"KPR-5714, a novel transient receptor potential melastatin 8 antagonist, improves overactive bladder via inhibition of bladder afferent hyperactivity in rats","volume":"373","author":"Nakanishi","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib862","first-page":"370","article-title":"Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy","volume":"69","author":"Nappi","year":"2017","journal-title":"Minerva Ginecol"},{"issue":"1, Suppl","key":"10.1124\/pharmrev.121.000523_bib863","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1177\/03946320120250S106","article-title":"Combined antimuscarinics for treatment of neurogenic overactive bladder","volume":"25","author":"Nardulli","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib864","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00345-009-0400-6","article-title":"Triple therapy in refractory detrusor overactivity: a preliminary study","volume":"28","author":"Natalin","year":"2010","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib865","doi-asserted-by":"crossref","first-page":"F126","DOI":"10.1152\/ajprenal.00633.2016","article-title":"Slowly cycling Rho kinase-dependent actomyosin cross-bridge \u201cslippage\u201d explains intrinsic high compliance of detrusor smooth muscle","volume":"313","author":"Neal","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib866","doi-asserted-by":"crossref","first-page":"223.e9","DOI":"10.1016\/j.urology.2017.08.011","article-title":"Impact of regular cannabis use on biomarkers of lower urinary tract function","volume":"109","author":"Nedumaran","year":"2017","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib867","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/gme.0b013e3182104977","article-title":"Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder","volume":"18","author":"Nelken","year":"2011","journal-title":"Menopause"},{"key":"10.1124\/pharmrev.121.000523_bib868","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12894-021-00899-0","article-title":"Systemic and intrathecal baclofen produce bladder antinociception in rats","volume":"21","author":"Ness","year":"2021","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib869","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.3390\/ijms21155474","article-title":"Mechanosensitivity is a characteristic feature of cultured suburothelial interstitial cells of the human bladder","volume":"21","author":"Neuhaus","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.121.000523_bib870","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpurol.2019.12.020","article-title":"Management and treatment of nocturnal enuresis\u2014an updated standardization document from the International Children\u2019s Continence Society","volume":"16","author":"Nev\u00e9us","year":"2020","journal-title":"J Pediatr Urol"},{"key":"10.1124\/pharmrev.121.000523_bib871","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1464-410X.2007.07358.x","article-title":"Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo","volume":"101","author":"Ney","year":"2008","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib872","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/pr.113.008268","article-title":"Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine","volume":"66","author":"Nilius","year":"2014","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib873","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","article-title":"Tolterodine\u2014a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data","volume":"60","author":"Nilvebrant","year":"1997","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000523_bib874","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-2999(86)90697-7","article-title":"Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites","volume":"123","author":"Nilvebrant","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib875","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1464-410X.2006.06643.x","article-title":"Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor","volume":"99","author":"Nishiguchi","year":"2007","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib876","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib877","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1464-410X.2009.09037.x","article-title":"Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity","volume":"105","author":"Nitti","year":"2010","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib878","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib879","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study","volume":"196","author":"Nitti","year":"2016","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib880","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib881","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the \u03b23-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib882","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1442-2042.1997.tb00289.x","article-title":"Therapeutic efficacy of clenbuterol for urinary incontinence after radical prostatectomy","volume":"4","author":"Noguchi","year":"1997","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib883","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.juro.2012.07.141","article-title":"Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia","volume":"189","author":"Nomiya","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib884","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.ju.0000067621.62736.7c","article-title":"A quantitative analysis of mRNA expression of \u03b1 1 and \u03b2-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders","volume":"170","author":"Nomiya","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib885","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.juro.2013.10.097","article-title":"Progressive vascular damage may lead to bladder underactivity in rats","volume":"191","author":"Nomiya","year":"2014","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib886","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0022-3565(25)23176-7","article-title":"Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs","volume":"256","author":"Noronha-Blob","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib887","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/mol.112.083758","article-title":"P2X receptors as drug targets","volume":"83","author":"North","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib888","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1067\/mob.2002.124840","article-title":"Duloxetine versus placebo in the treatment of stress urinary incontinence","volume":"187","author":"Norton","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib889","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/brain\/123.4.781","article-title":"Cerebral activation during micturition in normal men","volume":"123","author":"Nour","year":"2000","journal-title":"Brain"},{"key":"10.1124\/pharmrev.121.000523_bib890","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","article-title":"A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder","volume":"54","author":"Novara","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib891","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.maturitas.2020.05.001","article-title":"Potential effectiveness of ospemifene on detrusor overactivity in patients with vaginal atrophy","volume":"138","author":"Novara","year":"2020","journal-title":"Maturitas"},{"key":"10.1124\/pharmrev.121.000523_bib892","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/nau.24490","article-title":"Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction","volume":"39","author":"O\u2019Connor","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib893","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s002400000113","article-title":"Expression of m2 muscarinic acetylcholine receptor mRNA in primary culture of human prostate stromal cells","volume":"28","author":"Obara","year":"2000","journal-title":"Urol Res"},{"key":"10.1124\/pharmrev.121.000523_bib894","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000503453","article-title":"Sustainable effects of distigmine nromide on urinary bladder contractile function","volume":"105","author":"Obara","year":"2020","journal-title":"Pharmacology"},{"issue":"6 Pt B","key":"10.1124\/pharmrev.121.000523_bib895","first-page":"E293","article-title":"Expression profiling of G-protein-coupled receptors in human urothelium and related cell lines","volume":"110","author":"Ochodnick\u00fd","year":"2012","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib896","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"64","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib897","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00345-011-0654-7","article-title":"Efficacy of propiverine ER with or without \u03b1-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study","volume":"29","author":"Oelke","year":"2011","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib898","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00345-014-1296-3","article-title":"Nocturia improvement in the combination of Avodart(\u00ae) and tamsulosin (CombAT) study","volume":"32","author":"Oelke","year":"2014","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib899","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1743-6109.2007.00754.x","article-title":"Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum","volume":"5","author":"Oger","year":"2008","journal-title":"J Sex Med"},{"key":"10.1124\/pharmrev.121.000523_bib900","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1476-5381.2010.00748.x","article-title":"Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle","volume":"160","author":"Oger","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib901","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","article-title":"A multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23-adrenoceptor agonist solabegron for overactive bladder","volume":"62","author":"Ohlstein","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib902","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/dmd.107.016030","article-title":"Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects","volume":"35","author":"Ohmori","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.121.000523_bib903","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2007.02999.x","article-title":"Absolute bioavailability of imidafenacin after oral administration to healthy subjects","volume":"65","author":"Ohno","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib904","doi-asserted-by":"crossref","first-page":"F859","DOI":"10.1152\/ajprenal.00215.2017","article-title":"Do \u03b23-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?","volume":"313","author":"Okeke","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib905","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/nau.22900","article-title":"Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: a comparative study in the mice","volume":"36","author":"Oliveira","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib906","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.eururo.2018.07.037","article-title":"Detrusor underactivity and the underactive bladder: a systematic review of preclinical and clinical studies","volume":"74","author":"Osman","year":"2018","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib907","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/luts.12007","article-title":"Expression of \u03b2-adrenoceptor subtypes in urothelium, interstitial cells and detrusor of the human urinary bladder","volume":"5","author":"Otsuka","year":"2013","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib908","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00210-008-0274-y","article-title":"Expression and functional role of \u03b2-adrenoceptors in the human urinary bladder urothelium","volume":"377","author":"Otsuka","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib909","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11255-012-0343-5","article-title":"\u03b23-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men","volume":"45","author":"Otsuki","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/pharmrev.121.000523_bib910","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMra032662","article-title":"Management of overactive bladder","volume":"350","author":"Ouslander","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000523_bib911","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/nau.23095","article-title":"Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: analysis of an open label extension of a randomized trial (the RELAX study)","volume":"36","author":"Owen","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib912","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-010-0618-3","article-title":"Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity","volume":"29","author":"Padmanabhan","year":"2011","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib913","first-page":"1009","article-title":"Effect of non-psychotropic plant-derived cannabinoids on bladder contractility: focus on cannabigerol","volume":"10","author":"Pagano","year":"2015","journal-title":"Nat Prod Commun"},{"key":"10.1124\/pharmrev.121.000523_bib914","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0022-5347(17)35955-4","article-title":"Evidence for purinergic neurotransmission in human urinary bladder affected by interstitial cystitis","volume":"150","author":"Palea","year":"1993","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib915","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fphar.2016.00234","article-title":"Netupitant, a potent and highly selective NK1 receptor antagonist, alleviates acetic acid-induced bladder overactivity in anesthetized guinea-pigs","volume":"7","author":"Palea","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib916","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.bjp.0705297","article-title":"Actions of tramadol on micturition in awake, freely moving rats","volume":"139","author":"Pandita","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib917","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jcph.670","article-title":"Long-term data of efficacy, safety, and tolerability in a real-life setting of THC\/CBD oromucosal spray-treated multiple sclerosis patients","volume":"56","author":"Paolicelli","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib918","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/19336950.2016.1180488","article-title":"Big-conductance Ca2+-activated K+ channels in physiological and pathophysiological urinary bladder smooth muscle cells","volume":"10","author":"Parajuli","year":"2016","journal-title":"Channels (Austin)"},{"key":"10.1124\/pharmrev.121.000523_bib919","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/ijcp.12255","article-title":"A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder","volume":"68","author":"Park","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib920","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00345-018-2576-0","article-title":"Efficacy and safety of mirabegron, a \u03b23-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study","volume":"37","author":"Park","year":"2019","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib921","doi-asserted-by":"crossref","first-page":"11425","DOI":"10.1523\/JNEUROSCI.1384-09.2011","article-title":"TRP vanilloid 2 knock-out mice are susceptible to perinatal lethality but display normal thermal and mechanical nociception","volume":"31","author":"Park","year":"2011","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib922","series-title":"Urinary Tract","first-page":"15","article-title":"Animals models in overactive bladder research","author":"Parsons","year":"2011"},{"key":"10.1124\/pharmrev.121.000523_bib923","article-title":"Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia","volume":"11","author":"Pattanaik","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib924","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/01.ju.0000154631.92150.ef","article-title":"Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial","volume":"173","author":"Payne","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib925","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/S0022-5347(05)65136-1","article-title":"Effects of tiagabine, a gamma-aminobutyric acid re-uptake inhibitor, on normal rat bladder function","volume":"167","author":"Pehrson","year":"2002","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib926","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/01.ju.0000062528.54550.65","article-title":"Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation","volume":"170","author":"Pehrson","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib927","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0302-2838(03)00353-1","article-title":"Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction","volume":"44","author":"Pehrson","year":"2003","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib928","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000096940","article-title":"Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis","volume":"78","author":"Peng","year":"2007","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib929","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/nau.24519","article-title":"Alkalinized lidocaine solution as a first-line local anesthesia protocol for intradetrusor injection of onabotulinum toxin A: results from a double-blinded randomized controlled trial","volume":"39","author":"Pereira E Silva","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib930","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib931","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/JU.0000000000000463","article-title":"The impact of nocturia on mortality: a systematic review and meta-analysis","volume":"203","author":"Pesonen","year":"2020","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib932","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.tips.2006.07.002","article-title":"Rho kinase: a target for treating urinary bladder dysfunction?","volume":"27","author":"Peters","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000523_bib933","doi-asserted-by":"crossref","first-page":"R571","DOI":"10.1152\/ajpregu.00142.2014","article-title":"Central role of the BK channel in urinary bladder smooth muscle physiology and pathophysiology","volume":"307","author":"Petkov","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib934","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/iju.12950","article-title":"Failure of botulinum toxin injection for neurogenic detrusor overactivity: switch of toxin versus second injection of the same toxin","volume":"22","author":"Peyronnet","year":"2015","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib935","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/nau.23009","article-title":"Intradetrusor injections of onabotulinum toxin A (Botox\u00ae) 300 U or 200 U versus abobotulinum toxin A (Dysport\u00ae) 750 U in the management of neurogenic detrusor overactivity: a case control study","volume":"36","author":"Peyronnet","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib936","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.juro.2018.05.006","article-title":"Intradetrusor injections of botulinum toxin A in adults with spinal dysraphism","volume":"200","author":"Peyronnet","year":"2018","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib937","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib938","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00345-015-1666-5","article-title":"Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity","volume":"34","author":"Peyronnet","year":"2016","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib939","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/nau.24534","article-title":"Impact of intradetrusor botulinum toxin A injections on serum and urinary concentrations of nerve growth factor and brain-derived neurotrophic factor in patients with multiple sclerosis and neurogenic detrusor overactivity","volume":"40","author":"Philippova","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib940","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2010.02.031","article-title":"Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome\/interstitial cystitis","volume":"58","author":"Pinto","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib941","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.juro.2012.09.027","article-title":"Persistent therapeutic effect of repeated injections of onabotulinum toxin A in refractory bladder pain syndrome\/interstitial cystitis","volume":"189","author":"Pinto","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib942","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.juro.2017.10.018","article-title":"Intratrigonal onabotulinumtoxinA improves bladder symptoms and quality of life in patients with bladder pain syndrome\/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial","volume":"199","author":"Pinto","year":"2018","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib943","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.ju.0000108844.10235.f1","article-title":"Botulinum toxin type B for type A resistant bladder spasticity","volume":"171","author":"Pistolesi","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib944","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2053369118795349","article-title":"BMS\u2014consensus statement","volume":"24","author":"Pitkin","year":"2018","journal-title":"Post Reprod Health"},{"key":"10.1124\/pharmrev.121.000523_bib945","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.theriogenology.2010.06.017","article-title":"Expression of prostaglandin E2 receptor subtypes in the canine lower urinary tract varies according to the gonadal status and gender","volume":"74","author":"Ponglowhapan","year":"2010","journal-title":"Theriogenology"},{"key":"10.1124\/pharmrev.121.000523_bib946","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"10.1124\/pharmrev.121.000523_bib947","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fphar.2016.00118","article-title":"\u03b2-Adrenoceptor mediated relaxation of urinary bladder muscle in \u03b22-adrenoceptor knock-out mouse","volume":"7","author":"Propping","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib948","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141950","article-title":"Regulation of guinea pig detrusor smooth muscle excitability by 17\u03b2-estradiol: the role of the large conductance voltage- and Ca2+-activated K+ channels","volume":"10","author":"Provence","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib949","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-2952(00)00260-4","article-title":"Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms","volume":"59","author":"Purkiss","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib950","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/nau.23980","article-title":"Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder","volume":"38","author":"Pushkar","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib951","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.juro.2009.11.004","article-title":"Prostaglandin receptor EP1 and EP2 site in guinea pig bladder urothelium and lamina propria","volume":"183","author":"Rahnama\u2019i","year":"2010","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib952","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.prostaglandins.2012.08.005","article-title":"The distribution of the prostaglandin E receptor type 2 (EP2) in the detrusor of the guinea pig","volume":"99","author":"Rahnama\u2019i","year":"2012","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1124\/pharmrev.121.000523_bib953","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5489\/cuaj.6247","article-title":"A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study","volume":"14","author":"Ramsay","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1124\/pharmrev.121.000523_bib954","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.urology.2004.01.041","article-title":"Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience","volume":"63","author":"Rapp","year":"2004","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib955","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.04.019","article-title":"A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction","volume":"48","author":"Rapp","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib956","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0022-5347(05)00322-8","article-title":"Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder","volume":"175","author":"Rapp","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib957","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2017.12.028","article-title":"Safety and feasibility of intravesical instillation of botulinum toxin-A in hydrogel-based slow-release delivery system in patients with interstitial cystitis-bladder pain syndrome: a pilot study","volume":"114","author":"Rappaport","year":"2018","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib958","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bju.12028","article-title":"Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(\u00ae) or abobotulinumtoxinA (Dysport(\u00ae) make a difference?","volume":"112","author":"Ravindra","year":"2013","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib959","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/(SICI)1097-0045(19970215)30:3<160::AID-PROS3>3.0.CO;2-Q","article-title":"Muscarinic cholinergic receptors promote growth of human prostate cancer cells","volume":"30","author":"Rayford","year":"1997","journal-title":"Prostate"},{"key":"10.1124\/pharmrev.121.000523_bib960","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1464-410X.1973.tb12129.x","article-title":"The effect of progesterone on the adrenergic receptors of the urethra","volume":"45","author":"Raz","year":"1973","journal-title":"Br J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib961","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jpurol.2008.05.003","article-title":"Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity","volume":"4","author":"Reddy","year":"2008","journal-title":"J Pediatr Urol"},{"key":"10.1124\/pharmrev.121.000523_bib962","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.eururo.2007.08.052","article-title":"Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity","volume":"52","author":"Reitz","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib963","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/01.ju.0000108407.53880.6a","article-title":"Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity","volume":"171","author":"Reitz","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib964","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz","year":"2004","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib965","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1046\/j.1464-410X.2003.04170.x","article-title":"Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns","volume":"91","author":"Rembratt","year":"2003","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib966","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/nau.20168","article-title":"Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia","volume":"25","author":"Rembratt","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib967","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/AOG.0000000000000851","article-title":"Comparative effectiveness of anticholinergic therapy for overactive bladder in women. A systematic review and meta-analysis","volume":"125","author":"Reynolds","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib968","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.ju.0000108892.35041.2d","article-title":"Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia","volume":"171","author":"Riccabona","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib969","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.juro.2017.04.103","article-title":"Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence","volume":"198","author":"Richter","year":"2017","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib970","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.juro.2017.01.037","article-title":"Urinary biomarkers in women with refractory urgency urinary incontinence randomized to sacral neuromodulation versus onabotulinumtoxinA compared to controls","volume":"197","author":"Richter","year":"2017","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib971","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/nau.20300","article-title":"Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: a single dose, 4 weeks, double-blind, randomized, placebo controlled trial","volume":"26","author":"Rios","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib972","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2265.1998.00340.x","article-title":"Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects","volume":"48","author":"Rittig","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1124\/pharmrev.121.000523_bib973","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ejogrb.2011.07.030","article-title":"The efficacy and safety of PSD503 (phenylephrine 20%, w\/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study","volume":"159","author":"Robinson","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1124\/pharmrev.121.000523_bib974","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.maturitas.2009.12.022","article-title":"New drug treatments for urinary incontinence","volume":"65","author":"Robinson","year":"2010","journal-title":"Maturitas"},{"key":"10.1124\/pharmrev.121.000523_bib975","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1464-410X.2004.04768.x","article-title":"Antidiuresis: a new concept in managing female daytime urinary incontinence","volume":"93","author":"Robinson","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib976","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1464-410X.2007.07162.x","article-title":"A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome","volume":"100","author":"Robinson","year":"2007","journal-title":"BJU Int"},{"issue":"4, Suppl 1","key":"10.1124\/pharmrev.121.000523_bib977","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0090-4295(03)00676-9","article-title":"The role of estrogens in female lower urinary tract dysfunction","volume":"62","author":"Robinson","year":"2003","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib978","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/nau.23315","article-title":"Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients","volume":"37","author":"Robinson","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib979","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1520-6777(1996)15:3<215::AID-NAU6>3.0.CO;2-I","article-title":"Effects of estrogen and progestin replacement on the urogenital tract of the ovariectomized cynomolgus monkey","volume":"15","author":"Robinson","year":"1996","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib980","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.juro.2007.03.015","article-title":"The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis","volume":"178","author":"Robson","year":"2007","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib981","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.12500","volume":"113","author":"Roehrborn","year":"2014","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib982","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2008.10.037","volume":"55","author":"Roehrborn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib983","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib984","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.eururo.2008.11.009","article-title":"Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment","volume":"55","author":"Roosen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib985","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14740338.2018.1453496","article-title":"Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder","volume":"17","author":"Rosa","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1124\/pharmrev.121.000523_bib986","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2015.09.007","article-title":"Cardiovascular safety of \u03b23-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome","volume":"69","author":"Rosa","year":"2016","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib987","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bju.12730","article-title":"Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a \u03b23-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)","volume":"115","author":"Rossanese","year":"2015","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib988","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.phrs.2013.12.006","article-title":"Modulation of nerve-evoked contractions by \u03b23-adrenoceptor agonism in human and rat isolated urinary bladder","volume":"80","author":"Rouget","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1124\/pharmrev.121.000523_bib989","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2125.2011.04040.x","article-title":"An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects","volume":"72","author":"Round","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib990","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/nau.24272","volume":"39","author":"Rovner","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib991","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib992","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.juro.2008.05.050","article-title":"Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms","volume":"180","author":"Rovner","year":"2008","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib993","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.urology.2005.08.017","article-title":"Multicenter phase III trial studying trospium chloride in patients with overactive bladder","volume":"67","author":"Rudy","year":"2006","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib994","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00192-003-1054-3","article-title":"A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women","volume":"14","author":"Rufford","year":"2003","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib995","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ncpuro0456","article-title":"Mechanisms of disease: role of purinergic signaling in the pathophysiology of bladder dysfunction","volume":"3","author":"Ruggieri","year":"2006","journal-title":"Nat Clin Pract Urol"},{"key":"10.1124\/pharmrev.121.000523_bib996","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/978-3-642-16499-6_20","article-title":"Cannabinoids: potential targets for bladder dysfunction","volume":"202","author":"Ruggieri","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib997","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00192-014-2557-9","article-title":"Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?","volume":"26","author":"Sacco","year":"2015","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib998","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1124\/jpet.113.207340","article-title":"A functional analysis of the influence of \u03b23-adrenoceptors on the rat micturition cycle","volume":"347","author":"Sadananda","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib999","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bcp.12304","article-title":"Retraction statement: safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study","volume":"77","author":"Safarinejad","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1000","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0306-4522(02)00748-0","article-title":"Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites","volume":"116","author":"Saffroy","year":"2003","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000523_bib1001","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1464-410X.2009.08402.x","article-title":"Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial","volume":"103","author":"Sahai","year":"2009","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1002","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1003","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1464-410X.2002.03040.x","article-title":"Sildenafil influences lower urinary tract symptoms","volume":"90","author":"Sairam","year":"2002","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1004","first-page":"525","volume":"12","author":"Saito","year":"1999","journal-title":"Jpn J Urol Surg"},{"key":"10.1124\/pharmrev.121.000523_bib1005","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.juro.2008.08.002","article-title":"Pharmacological properties, functional alterations and gene expression of muscarinic receptors in young and old type 2 Goto-Kakizaki diabetic rat bladders","volume":"180","author":"Saito","year":"2008","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1006","first-page":"7","article-title":"[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]","volume":"57","author":"Sakai","year":"2011","journal-title":"Hinyokika Kiyo"},{"key":"10.1124\/pharmrev.121.000523_bib1007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10286-018-0551-x","article-title":"Neurogenic lower urinary tract dysfunction in multiple sclerosis, neuromyelitis optica, and related disorders","volume":"29","author":"Sakakibara","year":"2019","journal-title":"Clin Auton Res"},{"key":"10.1124\/pharmrev.121.000523_bib1008","first-page":"388","article-title":"The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis","volume":"74","author":"Sakalis","year":"2021","journal-title":"Cent European J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1009","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/iju.13721","article-title":"Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study","volume":"25","author":"Sakalis","year":"2018","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1010","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bju.14561","article-title":"Modulatory effects of intravesical P2X2\/3 purinergic receptor inhibition on lower urinary tract electromyographic properties and voiding function of female rats with moderate or severe spinal cord injury","volume":"123","author":"Salazar","year":"2019","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1011","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/nau.20681","article-title":"Voiding dysfunction in patients with Parkinson\u2019s disease: impact of neurological impairment and clinical parameters","volume":"28","author":"Sammour","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/jpet.113.208025","article-title":"Bradykinin contracts rat urinary bladder largely independently of phospholipase C","volume":"348","author":"Sand","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1013","doi-asserted-by":"crossref","first-page":"168.e1","DOI":"10.1016\/j.ajog.2011.08.005","article-title":"Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome","volume":"206","author":"Sand","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib1014","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.juro.2013.02.037","article-title":"Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study","volume":"190","author":"Sand","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11597970-000000000-00000","article-title":"Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies","volume":"29","author":"Sand","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1124\/pharmrev.121.000523_bib1016","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1464-410X.2010.09519.x","article-title":"Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged \u2265 75 years) with overactive bladder syndrome","volume":"107","author":"Sand","year":"2011","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1017","doi-asserted-by":"crossref","DOI":"10.1097\/j.pbj.0000000000000070","article-title":"Understanding underactive bladder: a review of the contemporary literature","volume":"5","author":"Santos-Pereira","year":"2020","journal-title":"Porto Biomed J"},{"key":"10.1124\/pharmrev.121.000523_bib1018","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.eururo.2013.06.043","article-title":"Protective effect of a \u03b23-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia","volume":"64","author":"Sawada","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1019","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.maturitas.2008.04.012","article-title":"Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence","volume":"60","author":"Schagen van Leeuwen","year":"2008","journal-title":"Maturitas"},{"key":"10.1124\/pharmrev.121.000523_bib1020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09513590.2018.1500534","article-title":"Usefulness of ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgery","volume":"35","author":"Schiavi","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"10.1124\/pharmrev.121.000523_bib1021","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/09513590.2018.1441398","article-title":"Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?","volume":"34","author":"Schiavi","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"10.1124\/pharmrev.121.000523_bib1022","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1080\/09513590.2017.1323859","article-title":"Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms","volume":"33","author":"Schiavi","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"10.1124\/pharmrev.121.000523_bib1023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics","volume":"176","author":"Schmid","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1024","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF00169379","article-title":"Differential calcium signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type","volume":"352","author":"Schmidt","year":"1995","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1442-2042.2008.02246.x","article-title":"Nocturia: a non-specific but important symptom of urological disease","volume":"16","author":"Schneider","year":"2009","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1026","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/jpet.103.063735","article-title":"Signal transduction underlying carbachol-induced contraction of human urinary bladder","volume":"309","author":"Schneider","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fphar.2011.00011","article-title":"Human urinary bladder strip relaxation by the \u03b2-adrenoceptor agonist isoprenaline: methodological considerations and effects of gender and age","volume":"2","author":"Schneider","year":"2011","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1028","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/01.ju.0000158138.07187.f5","article-title":"A role for muscarinic receptors or rho-kinase in hypertension associated rat bladder dysfunction?","volume":"173","author":"Schneider","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1029","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00210-005-1084-0","article-title":"Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder","volume":"372","author":"Schneider","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/jpet.103.058248","article-title":"Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca2+ sources","volume":"308","author":"Schneider","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1031","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/j.1742-1241.2010.02442.x","article-title":"Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?","volume":"64","author":"Schneider","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib1032","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fphar.2010.00128","article-title":"Can [125I]-iodocyanopindolol label \u03b23-adrenoceptors in rat urinary bladder?","volume":"1","author":"Schneider","year":"2010","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1033","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/nau.24960","article-title":"Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment","volume":"41","author":"Sch\u00f6nburg","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1034","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00005392-200102000-00087","article-title":"Effect of chronic bladder outlet obstruction on blood flow of the rabbit bladder","volume":"165","author":"Schr\u00f6der","year":"2001","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1464-410X.2006.06342.x","article-title":"Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction","volume":"98","author":"Schr\u00f6der","year":"2006","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1036","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/01.ju.0000134186.58854.2c","article-title":"Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice","volume":"172","author":"Schr\u00f6der","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1037","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0090-4295(01)01641-7","article-title":"Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results","volume":"59","author":"Schulte-Baukloh","year":"2002","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1038","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0302-2838(03)00136-2","article-title":"Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder","volume":"44","author":"Schulte-Baukloh","year":"2003","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1039","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1464-410X.2007.07137.x","article-title":"Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment","volume":"100","author":"Schulte-Baukloh","year":"2007","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1040","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1041","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2007.04.026","article-title":"Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence","volume":"52","author":"Schurch","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1042","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A","volume":"342","author":"Schurch","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000523_bib1043","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1044","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.juro.2009.11.026","article-title":"Overactive bladder medication adherence when medication is free to patients","volume":"183","author":"Sears","year":"2010","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11934-020-01009-7","article-title":"Tadalafil alone or in combination with tamsulosin for the management for LUTS\/BPH and ED","volume":"21","author":"Sebastianelli","year":"2020","journal-title":"Curr Urol Rep"},{"key":"10.1124\/pharmrev.121.000523_bib1046","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00210-018-1510-8","article-title":"Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium","volume":"391","author":"Sellers","year":"2018","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1047","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2008.06.051","article-title":"Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?","volume":"55","author":"Serati","year":"2009","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1048","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.autneu.2009.09.022","article-title":"The medical management of urinary incontinence","volume":"152","author":"Shaban","year":"2010","journal-title":"Auton Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib1049","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7326\/0003-4819-148-6-200803180-00211","article-title":"Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women","volume":"148","author":"Shamliyan","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1124\/pharmrev.121.000523_bib1050","doi-asserted-by":"crossref","first-page":"466.e1","DOI":"10.1016\/j.urology.2012.10.027","article-title":"Effects of vitamin D analog on bladder function and sensory signaling in animal models of cystitis","volume":"81","author":"Shapiro","year":"2013","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1051","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11884-019-00572-1","article-title":"Underactive bladder and bladder outlet procedures in women","volume":"15","author":"Shapiro","year":"2020","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"10.1124\/pharmrev.121.000523_bib1052","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.urology.2019.06.033","article-title":"Intravesical electromotive botulinum toxin type A (Dysport) administration in children with myelomeningocele","volume":"132","author":"Sharifi-Rad","year":"2019","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1053","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00192-018-3653-z","article-title":"A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder","volume":"29","author":"Shepherd","year":"2018","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib1054","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nbd.2012.07.010","article-title":"Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A","volume":"48","author":"Shimizu","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.121.000523_bib1055","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib1056","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1124\/jpet.119.261610","article-title":"Activation of prejunctional P2x2\/3 heterotrimers by ATP enhances the cholinergic tone in obstructed human urinary bladders","volume":"372","author":"Silva-Ramos","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1057","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0022-5347(05)64683-6","article-title":"The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input","volume":"168","author":"Silva","year":"2002","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1058","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-7-9","article-title":"Bladder sensory desensitization decreases urinary urgency","volume":"7","author":"Silva","year":"2007","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1059","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2005.04.012","article-title":"Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial","volume":"48","author":"Silva","year":"2005","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1060","doi-asserted-by":"crossref","first-page":"F388","DOI":"10.1152\/ajprenal.00392.2016","article-title":"Inhibition of cholinergic neurotransmission by \u03b23-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders","volume":"313","author":"Silva","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000523_bib1061","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/13697137.2013.807606","article-title":"Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy","volume":"16","author":"Simon","year":"2013","journal-title":"Climacteric"},{"key":"10.1124\/pharmrev.121.000523_bib1062","doi-asserted-by":"crossref","first-page":"118179","DOI":"10.1016\/j.lfs.2020.118179","article-title":"Excitatory effect of acotiamide on rat and human bladder: implications for underactive bladder treatment","volume":"258","author":"Singh","year":"2020","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000523_bib1063","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/S0022-5347(17)53509-0","article-title":"Atropine resistance of transmurally stimulated isolated human bladder muscle","volume":"128","author":"Sj\u00f6gren","year":"1982","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1064","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00003088-200645040-00001","article-title":"The clinical pharmacokinetics of darifenacin","volume":"45","author":"Skerjanec","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pharmrev.121.000523_bib1065","first-page":"37","article-title":"Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder","volume":"77","author":"Smet","year":"1997","journal-title":"Lab Invest"},{"key":"10.1124\/pharmrev.121.000523_bib1066","doi-asserted-by":"crossref","first-page":"C467","DOI":"10.1152\/ajpcell.00169.2012","article-title":"Novel role for the transient potential receptor melastatin 4 channel in guinea pig detrusor smooth muscle physiology","volume":"304","author":"Smith","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1067","doi-asserted-by":"crossref","first-page":"F918","DOI":"10.1152\/ajprenal.00417.2012","article-title":"TRPM4 channel: a new player in urinary bladder smooth muscle function in rats","volume":"304","author":"Smith","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1068","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/01.ju.0000049202.56189.54","article-title":"Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1069","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.neuint.2007.11.006","article-title":"Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury","volume":"52","author":"Smith","year":"2008","journal-title":"Neurochem Int"},{"key":"10.1124\/pharmrev.121.000523_bib1070","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.urology.2004.08.016","article-title":"Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra","volume":"65","author":"Smith","year":"2005","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1071","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000293207","article-title":"Steroid hormone receptors in pelvic muscles and ligaments in women","volume":"30","author":"Smith","year":"1990","journal-title":"Gynecol Obstet Invest"},{"key":"10.1124\/pharmrev.121.000523_bib1072","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/nau.22653","article-title":"Does defective volume sensation contribute to detrusor underactivity?","volume":"34","author":"Smith","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1073","doi-asserted-by":"crossref","first-page":"R577","DOI":"10.1152\/ajpregu.00508.2011","article-title":"Detrusor expulsive strength is preserved, but responsiveness to bladder filling and urinary sensitivity is diminished in the aging mouse","volume":"302","author":"Smith","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000523_bib1074","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s11255-014-0809-8","article-title":"Advanced therapeutic directions to treat the underactive bladder","volume":"46","author":"Smith","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.121.000523_bib1075","first-page":"S43","article-title":"Can we improve our diagnosis of impaired detrusor contractility in women? An ICI-RS 2019 proposal","volume":"39","author":"Smith","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1076","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.juro.2013.07.017","article-title":"Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy","volume":"190","author":"Smits","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1077","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1177\/0091270004267592","article-title":"Pharmacokinetics and safety of solifenacin succinate in healthy young men","volume":"44","author":"Smulders","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1078","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0361-9230(02)00833-X","article-title":"Effect of cryoinjury on the contractile parameters of bladder strips: a model of impaired detrusor contractility","volume":"59","author":"Somogyi","year":"2002","journal-title":"Brain Res Bull"},{"key":"10.1124\/pharmrev.121.000523_bib1079","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/nau.1930140606","article-title":"Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity","volume":"14","author":"Stahl","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1080","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","article-title":"Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR)","volume":"205","author":"Staskin","year":"2021","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1081","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, double-blind, placebo- and active-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1082","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1532-5415.2010.02988.x","article-title":"Trospium chloride is undetectable in the older human central nervous system","volume":"58","author":"Staskin","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1124\/pharmrev.121.000523_bib1083","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2008.11.125","article-title":"Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study","volume":"181","author":"Staskin","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1084","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1517\/14656560903451682","article-title":"Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder","volume":"10","author":"Staskin","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pharmrev.121.000523_bib1085","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/j.1742-1241.2009.02189.x","article-title":"Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials","volume":"63","author":"Staskin","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib1086","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11884-009-0018-y","article-title":"Role of ion channels in bladder function and voiding disorders","volume":"4","author":"Steers","year":"2009","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"10.1124\/pharmrev.121.000523_bib1087","first-page":"R20","article-title":"Calcium channel antagonists prevent urinary bladder growth and neuroplasticity following mechanical stress","volume":"266","author":"Steers","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1088","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1464-410X.2005.05343.x","article-title":"An investigation of dose titration with darifenacin, an M3-selective receptor antagonist","volume":"95","author":"Steers","year":"2005","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1089","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1464-410X.2007.06980.x","article-title":"Duloxetine compared with placebo for treating women with symptoms of overactive bladder","volume":"100","author":"Steers","year":"2007","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1090","doi-asserted-by":"crossref","first-page":"R1443","DOI":"10.1152\/ajpregu.00486.2001","article-title":"M(3)-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea","volume":"282","author":"Stengel","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1091","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1474-8673.2006.00371.x","article-title":"Muscarinic receptor function, density and G-protein coupling in the overactive diabetic rat bladder","volume":"26","author":"Stevens","year":"2006","journal-title":"Auton Autacoid Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1092","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/ejhf.1809","article-title":"Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial","volume":"22","author":"Stewart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/pharmrev.121.000523_bib1093","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000282207","article-title":"Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial","volume":"47","author":"St\u00f6hrer","year":"1991","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib1094","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sc.2012.174","article-title":"Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity","volume":"51","author":"St\u00f6hrer","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1124\/pharmrev.121.000523_bib1095","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1111\/j.1464-410X.2011.10838.x","article-title":"Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction","volume":"110","author":"Streng","year":"2012","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1096","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.eururo.2007.10.024","article-title":"Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder","volume":"53","author":"Streng","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1097","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eururo.2011.09.002","article-title":"Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats","volume":"61","author":"Strittmatter","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1098","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fphys.2020.00705","article-title":"Prostaglandin E2 and F2alpha modulate urinary bladder urothelium, lamina propria and detrusor contractility via the FP receptor","volume":"11","author":"Stromberga","year":"2020","journal-title":"Front Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1099","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11934-013-0363-4","article-title":"Mirabegron for male lower urinary tract symptoms","volume":"14","author":"Suarez","year":"2013","journal-title":"Curr Urol Rep"},{"key":"10.1124\/pharmrev.121.000523_bib1100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0378-5122(94)90008-6","article-title":"Estrogen and urinary incontinence in women","volume":"20","author":"Sultana","year":"1994","journal-title":"Maturitas"},{"key":"10.1124\/pharmrev.121.000523_bib1101","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/030079902125000570","article-title":"Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET)","volume":"18","author":"Sussman","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pharmrev.121.000523_bib1102","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2012.11.060","article-title":"The novel \u03b23-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity","volume":"699","author":"Sval\u00f8","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1742-7843.2006.pto_285.x","article-title":"Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers","volume":"99","author":"Swart","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.121.000523_bib1104","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1464-410X.2003.04683.x","article-title":"Nocturnal polyuria in community-dwelling women","volume":"93","author":"Swithinbank","year":"2004","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0031-6997(24)01403-0","article-title":"Vanilloid (Capsaicin) receptors and mechanisms","volume":"51","author":"Szallasi","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib1106","first-page":"420","article-title":"Application of methylene blue as an improvement of the injection technique of botulinum toxin A in the treatment of refractory idiopathic overactive bladder: prospective, single-blind (patient-blind), randomized trial","volume":"14","author":"Szczypior","year":"2019","journal-title":"Wideochir Inne Tech Malo Inwazyjne"},{"key":"10.1124\/pharmrev.121.000523_bib1107","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.neuroimage.2007.10.059","article-title":"Abnormal connections in the supraspinal bladder control network in women with urge urinary incontinence","volume":"39","author":"Tadic","year":"2008","journal-title":"Neuroimage"},{"key":"10.1124\/pharmrev.121.000523_bib1108","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/nau.20365","article-title":"RhoA\/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate","volume":"26","author":"Takahashi","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1109","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1110","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of YM178, a novel selective \u03b23-adrenoceptor agonist, on bladder function","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1111","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/nau.10034","article-title":"Effects of \u03b2(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats","volume":"21","author":"Takeda","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1112","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","article-title":"Evidence for \u03b23-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods","volume":"288","author":"Takeda","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1113","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","article-title":"In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective \u03b23-adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/pharmrev.121.000523_bib1114","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.111.043588","article-title":"Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective \u03b2(3)-adrenoceptor agonist, after oral administration to healthy male volunteers","volume":"40","author":"Takusagawa","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.121.000523_bib1115","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3109\/00498254.2012.675095","article-title":"Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective \u03b23-adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/pharmrev.121.000523_bib1116","doi-asserted-by":"crossref","first-page":"884057","DOI":"10.3389\/fphys.2022.884057","article-title":"Inhibition of human prostate and bladder smooth muscle contraction, vasoconstriction of porcine renal and coronary arteries, and growth-related functions of prostate stromal cells by presumed small molecule G\u03b1q\/11 inhibitor, YM-254890","volume":"13","author":"Tamalunas","year":"2022","journal-title":"Front Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1117","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000398811","article-title":"Effects of Silodosin, an \u03b11A-adrenoceptor antagonist, and distigmine, an acetylcholinesterase inhibitor, and their combined effects on impaired voiding function in Zucker diabetic fatty rats","volume":"95","author":"Tatemichi","year":"2015","journal-title":"Pharmacology"},{"key":"10.1124\/pharmrev.121.000523_bib1118","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1464-410X.1979.tb03588.x","article-title":"A double-blind crossover trial of baclofen\u2014a new treatment for the unstable bladder syndrome","volume":"51","author":"Taylor","year":"1979","journal-title":"Br J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1119","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/14656566.2016.1186645","article-title":"Current and future pharmacotherapy for treating overactive bladder","volume":"17","author":"Thiagamoorthy","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pharmrev.121.000523_bib1120","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1517\/13543784.2015.1076390","article-title":"Early investigational \u03b23 adreno-receptor agonists for the management of the overactive bladder syndrome","volume":"24","author":"Thiagamoorthy","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib1121","doi-asserted-by":"crossref","first-page":"R416","DOI":"10.1152\/ajpregu.00111.2010","article-title":"Neural control of the female urethral and anal rhabdosphincters and pelvic floor muscles","volume":"299","author":"Thor","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1122","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0022-3565(25)10548-X","article-title":"Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat","volume":"274","author":"Thor","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1123","doi-asserted-by":"crossref","first-page":"159ra148","DOI":"10.1126\/scitranslmed.3004276","article-title":"An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure","volume":"4","author":"Thorneloe","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.121.000523_bib1124","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1124\/jpet.108.139295","volume":"326","author":"Thorneloe","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1125","first-page":"761","article-title":"The alpha2-delta protein: an auxiliary subunit of voltage-dependent calcium channels as a recognized drug target","volume":"11","author":"Thorpe","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/pharmrev.121.000523_bib1126","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.ju.0000161213.54024.7f","article-title":"Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors?","volume":"174","author":"Thumfart","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1127","doi-asserted-by":"crossref","first-page":"F738","DOI":"10.1152\/ajprenal.00333.2015","article-title":"LUTS in pelvic ischemia: a new concept in voiding dysfunction","volume":"310","author":"Thurmond","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000523_bib1128","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1007\/PL00014139","article-title":"Medical treatment and medical side effects in urinary incontinence in the elderly","volume":"16","author":"Th\u00fcroff","year":"1998","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12894-020-00683-6","article-title":"Can clinical and urodynamic parameters predict the occurrence of neutralizing antibodies in therapy failure of intradetrusor onabotulinumtoxin A injections in patients with spinal cord injury?","volume":"20","author":"Tiburtius","year":"2020","journal-title":"BMC Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1130","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2009.03.080","article-title":"Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland","volume":"57","author":"Tikkinen","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1131","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1132","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF00167244","article-title":"Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle","volume":"348","author":"Tokuno","year":"1993","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1133","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/nau.24565","article-title":"A large survey of nocturia related to sleep quality and daytime quality of life in a young Japanese population: NOCTURNE study","volume":"40","author":"Torimoto","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1134","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3485","article-title":"Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"1","author":"Torres-Moreno","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1124\/pharmrev.121.000523_bib1135","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.bjp.0706297","article-title":"Distinct mixtures of muscarinic receptor subtypes mediate inhibition of noradrenaline release in different mouse peripheral tissues, as studied with receptor knockout mice","volume":"145","author":"Trendelenburg","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1136","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/PL00007088","article-title":"Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder","volume":"18","author":"Truss","year":"2000","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1137","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s003450100221","article-title":"Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside","volume":"19","author":"Truss","year":"2001","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1138","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2007.09.037","article-title":"Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence","volume":"53","author":"Tsakiris","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1139","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/nau.20583","article-title":"Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome","volume":"28","author":"Tseng","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1140","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1212\/WNL.0000000000005991","article-title":"Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS","volume":"91","author":"Tullman","year":"2018","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.121.000523_bib1141","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.juro.2016.11.092","article-title":"Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder","volume":"197","author":"Tyagi","year":"2017","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1142","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/S1677-55382009000100012","article-title":"Investigations into the presence of functional \u03b21, \u03b22 and \u03b23-adrenoceptors in urothelium and detrusor of human bladder","volume":"35","author":"Tyagi","year":"2009","journal-title":"Int Braz J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1143","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.juro.2008.11.078","article-title":"Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium","volume":"181","author":"Tyagi","year":"2009","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1144","series-title":"Pharmacology\/toxicology NDA\/BLA review and evaluation (NDA 202-611)","year":"2012"},{"key":"10.1124\/pharmrev.121.000523_bib1145","series-title":"Mirabegron prescribing information","year":"2015"},{"key":"10.1124\/pharmrev.121.000523_bib1146","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejphar.2005.06.029","article-title":"Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via \u03b2-adrenoceptors","volume":"518","author":"Uchida","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1147","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.eururo.2006.05.025","article-title":"Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future","volume":"50","author":"\u00dcckert","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1148","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2005.12.050","article-title":"Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate","volume":"49","author":"\u00dcckert","year":"2006","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1149","first-page":"456","article-title":"Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder","volume":"50","author":"\u00dcckert","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/pharmrev.121.000523_bib1150","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1021\/jm0509445","article-title":"Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists","volume":"49","author":"Uehling","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.121.000523_bib1151","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1124\/pharmrev.121.000523_bib1152","article-title":"Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction","volume":"5","author":"Utomo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib1153","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/luts.12257","article-title":"Pathophysiological mechanisms in detrusor underactivity: novel experimental findings","volume":"11","author":"Vale","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib1154","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/archneur.1996.00550120082020","article-title":"Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial","volume":"53","author":"Valiquette","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1124\/pharmrev.121.000523_bib1155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11319110-000000000-00000","article-title":"Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis? A focus on safety issues","volume":"33","author":"Van de Walle","year":"2010","journal-title":"Drug Saf"},{"key":"10.1124\/pharmrev.121.000523_bib1156","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00210-008-0327-2","article-title":"Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716)","volume":"378","author":"van Diepen","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1157","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1471-0528.2004.00067.x","article-title":"Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence","volume":"111","author":"van Kerrebroeck","year":"2004","journal-title":"BJOG"},{"key":"10.1124\/pharmrev.121.000523_bib1158","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.eururo.2013.07.034","article-title":"Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial","volume":"64","author":"van Kerrebroeck","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1159","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2013.03.031","article-title":"Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN)","volume":"64","author":"Van Kerrebroeck","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1161","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.eururo.2007.01.027","article-title":"Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study","volume":"52","author":"van Kerrebroeck","year":"2007","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1162","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2013.10.039","article-title":"The new radioligand [(3)H]-L 748,337 differentially labels human and rat \u03b23-adrenoceptors","volume":"720","author":"van Wieringen","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1163","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/157488607781668891","article-title":"Desmopressin 30 years in clinical use: a safety review","volume":"2","author":"Vande Walle","year":"2007","journal-title":"Curr Drug Saf"},{"key":"10.1124\/pharmrev.121.000523_bib1164","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40266-020-00829-z","article-title":"Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged \u226565 and \u226575 years: subpopulation analysis from the EMPOWUR randomized, international, phase III study","volume":"38","author":"Varano","year":"2021","journal-title":"Drugs Aging"},{"key":"10.1124\/pharmrev.121.000523_bib1165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1067\/mob.2003.374","article-title":"Short-term urogenital effects of raloxifene, tamoxifen, and estrogen","volume":"189","author":"Vardy","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib1166","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.urology.2011.07.1415","article-title":"Vitamin D and lower urinary tract symptoms among US men: results from the 2005-2006 National Health and Nutrition Examination Survey","volume":"78","author":"Vaughan","year":"2011","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1167","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.juro.2013.10.046","article-title":"Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review","volume":"191","author":"Veenboer","year":"2014","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1168","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00192-008-0564-4","article-title":"Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine","volume":"19","author":"Vella","year":"2008","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1124\/pharmrev.121.000523_bib1169","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.ju.0000143189.19835.f3","article-title":"Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation","volume":"173","author":"Vemulakonda","year":"2005","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0163-7258(02)00174-2","article-title":"Cholinergic innervation and function in the prostate gland","volume":"94","author":"Ventura","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1171","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(00)02732-3","article-title":"Anatomical evidence for two spinal \u201cafferent-interneuron-efferent\u201d reflex pathways involved in micturition in the rat: a \u201cpelvic nerve\u201d reflex pathway and a \u201csacrolumbar intersegmental\u201d reflex pathway","volume":"883","author":"Vera","year":"2000","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.121.000523_bib1172","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000449413","article-title":"Tetrahydrocannabinol: cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice","volume":"76","author":"Vermersch","year":"2016","journal-title":"Eur Neurol"},{"key":"10.1124\/pharmrev.121.000523_bib1173","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/nau.21194","article-title":"Antimuscarinic effects on current perception threshold: a prospective placebo control study","volume":"31","author":"Vijaya","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1174","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","article-title":"Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence","volume":"367","author":"Visco","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000523_bib1175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-3-540-34891-7_20","article-title":"TRPM8","volume":"202","author":"Voets","year":"2007","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1176","article-title":"Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals","volume":"4","author":"Vollert","year":"2020","journal-title":"BMJ Open Sci"},{"key":"10.1124\/pharmrev.121.000523_bib1177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2018.09.005","article-title":"Antimuscarinic use and discontinuation in an older adult population","volume":"80","author":"Vouri","year":"2019","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1124\/pharmrev.121.000523_bib1178","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/nau.23717","article-title":"Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson\u2019s disease","volume":"37","author":"Vurture","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1179","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/luts.12047","article-title":"Improvement of overactive bladder symptoms and bladder ischemia with dutasteride in patients with benign prostatic enlargement","volume":"7","author":"Wada","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib1180","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/nau.23066","article-title":"Combinational effects of muscarinic receptor inhibition and \u03b23-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury","volume":"36","author":"Wada","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1181","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.AOG.0000109429.67671.d1","article-title":"Effect of raloxifene on urinary incontinence: a randomized controlled trial","volume":"103","author":"Waetjen","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1124\/pharmrev.121.000523_bib1182","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1183","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jgs.12088","article-title":"Flexible-dose fesoterodine in elderly subjects with overactive bladder: results of the randomized, double-blind, placebo-controlled SOFIA trial","volume":"61","author":"Wagg","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1124\/pharmrev.121.000523_bib1184","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/nau.22383","article-title":"Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial","volume":"33","author":"Wagg","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","article-title":"Efficacy, safety, and tolerability of mirabegron in patients aged \u226565yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)","volume":"77","author":"Wagg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1186","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","article-title":"Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis","volume":"4","author":"Wagg","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1124\/pharmrev.121.000523_bib1187","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/nau.24706","article-title":"What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine","volume":"40","author":"Wagg","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1188","first-page":"223","article-title":"The muscarinic receptor subtypes in human blood vessels","volume":"56","author":"Walch","year":"2001","journal-title":"Therapie"},{"key":"10.1124\/pharmrev.121.000523_bib1189","doi-asserted-by":"crossref","first-page":"1744-8069","DOI":"10.1186\/1744-8069-7-31","article-title":"Local activation of cannabinoid CB1 receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents","volume":"7","author":"Walczak","year":"2011","journal-title":"Mol Pain"},{"key":"10.1124\/pharmrev.121.000523_bib1190","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-5347(01)65148-6","article-title":"Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland","volume":"157","author":"Waldeck","year":"1997","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1191","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1124\/dmd.31.6.714","article-title":"Influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats","volume":"31","author":"Walter","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.121.000523_bib1192","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/s-2008-1057846","article-title":"Die neurogene Blase in vitro","volume":"26","author":"Wammack","year":"1995","journal-title":"Aktuelle Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1193","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/luts.12103","article-title":"Efficacy and adherence of flexibly adding on a second antimuscarinic agent for patients with refractory overactive bladder","volume":"9","author":"Wang","year":"2017","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1124\/pharmrev.121.000523_bib1194","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.juro.2010.08.095","article-title":"Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study","volume":"185","author":"Wang","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1195","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1074\/jbc.M110.181784","article-title":"A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic","volume":"286","author":"Wang","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.121.000523_bib1196","article-title":"Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000523_bib1197","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/bph.13099","article-title":"Inhibition of prostate smooth muscle contraction and prostate stromal cell growth by the inhibitors of Rac, NSC23766 and EHT1864","volume":"172","author":"Wang","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1198","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neulet.2015.01.009","article-title":"Activation of cannabinoid receptor 1 inhibits increased bladder activity induced by nerve growth factor","volume":"589","author":"Wang","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.121.000523_bib1199","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12031-014-0453-x","article-title":"Attenuation of cystitis and pain sensation in mice lacking fatty acid amide hydrolase","volume":"55","author":"Wang","year":"2015","journal-title":"J Mol Neurosci"},{"key":"10.1124\/pharmrev.121.000523_bib1200","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.urology.2010.01.080","article-title":"Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder","volume":"76","author":"Watanabe","year":"2010","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1201","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/nau.20038","article-title":"The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis","volume":"23","author":"Weatherall","year":"2004","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1202","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000445074","article-title":"The effect of vaginal oestriol cream on subjective and objective symptoms of stress urinary incontinence and vaginal atrophy: an international multi-centre pilot study","volume":"82","author":"Weber","year":"2017","journal-title":"Gynecol Obstet Invest"},{"key":"10.1124\/pharmrev.121.000523_bib1203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-009-0466-1","article-title":"Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany","volume":"28","author":"Wefer","year":"2010","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1204","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1096\/fj.04-1516fje","article-title":"An essential role of Cav1.2 L-type calcium channel for urinary bladder function","volume":"18","author":"Wegener","year":"2004","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.121.000523_bib1205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1464-410X.2011.10175.x","article-title":"The evaluation and treatment of nocturia: a consensus statement","volume":"108","author":"Weiss","year":"2011","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1206","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.euf.2021.12.016","article-title":"The prevalence of nocturnal polyuria in the United States: results from the epidemiology of nocturnal polyuria study","volume":"8","author":"Weiss","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1124\/pharmrev.121.000523_bib1207","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.urology.2019.09.022","article-title":"Management of nocturia and nocturnal polyuria","volume":"133S","author":"Weiss","year":"2019","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1208","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.juro.2012.12.112","article-title":"Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study","volume":"190","author":"Weiss","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1209","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.juro.2012.11.067","article-title":"Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency","volume":"189","author":"Weiss","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1210","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.juro.2011.05.083","article-title":"Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia","volume":"186","author":"Weiss","year":"2011","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1211","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/nau.22243","article-title":"Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Weiss","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1212","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1002\/nau.23774","article-title":"A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction","volume":"37","author":"Welk","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1213","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/j.1476-5381.1995.tb16379.x","article-title":"Factors involved in the relaxation of female pig urethra evoked by electrical field stimulation","volume":"116","author":"Werkstr\u00f6m","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1214","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1464-410X.2006.06217.x","article-title":"Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects","volume":"98","author":"Werkstr\u00f6m","year":"2006","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1215","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.juro.2008.08.030","article-title":"Short-term efficacy of botulinum toxin A for refractory overactive bladder in the elderly population","volume":"180","author":"White","year":"2008","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1216","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib1217","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010567","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia\u2014an overview of Cochrane reviews","volume":"2013","author":"Wiffen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000523_bib1218","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/jpet.114.216010","article-title":"Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans","volume":"351","author":"Winchester","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1219","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1464-410X.2003.03802.x","article-title":"The role of the human bladder lamina propria myofibroblast","volume":"91","author":"Wiseman","year":"2003","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1220","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.eururo.2007.12.007","article-title":"Cholinergic innervation and muscarinic receptors in the human prostate","volume":"54","author":"Witte","year":"2008","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1221","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00210-011-0689-8","article-title":"Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation","volume":"384","author":"Witte","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1222","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/MOU.0b013e32831a6ff3","article-title":"Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?","volume":"19","author":"Witte","year":"2009","journal-title":"Curr Opin Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1223","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1757-5672.2009.00051.x","article-title":"Does the number of previous vaginal deliveries affect overactive bladder symptoms or their response to treatment?","volume":"1","author":"Witte","year":"2009","journal-title":"LUTS"},{"key":"10.1124\/pharmrev.121.000523_bib1224","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sc.2015.195","article-title":"Initial experience with the treatment of neurogenic detrusor overactivity with a new \u03b2-3 agonist (mirabegron) in patients with spinal cord injury","volume":"54","author":"W\u00f6llner","year":"2016","journal-title":"Spinal Cord"},{"key":"10.1124\/pharmrev.121.000523_bib1225","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0022-5347(05)65936-8","article-title":"Efficacy of the \u03b23-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat","volume":"166","author":"Woods","year":"2001","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1226","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/pr.110.003517","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress","volume":"63","author":"Woodward","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000523_bib1227","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00210-017-1361-8","article-title":"Rho kinase inhibition ameliorates cyclophosphamide-induced cystitis in rats","volume":"390","author":"Wr\u00f3bel","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1228","doi-asserted-by":"crossref","first-page":"224.e7","DOI":"10.1016\/j.urology.2016.03.008","article-title":"The influence of maxacalcitol, vitamin D3 analog, on detrusor overactivity in conscious rats","volume":"93","author":"Wr\u00f3bel","year":"2016","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1229","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/nau.22978","article-title":"The effect of combined treatment with a \u03b23 AR agonist and a ROCK inhibitor on detrusor overactivity","volume":"36","author":"Wr\u00f3bel","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1230","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/nau.22918","article-title":"The influence of Rho-kinase inhibition on acetic acid-induced detrusor overactivity","volume":"36","author":"Wr\u00f3bel","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1231","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2018.08.027","article-title":"Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats","volume":"837","author":"Wr\u00f3bel","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1232","doi-asserted-by":"crossref","first-page":"105329","DOI":"10.1016\/j.ejps.2020.105329","article-title":"Stimulation of atypical cannabinoid receptor GPR55 abolishes the symptoms of detrusor overactivity in spontaneously hypertensive rats","volume":"150","author":"Wr\u00f3bel","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/pharmrev.121.000523_bib1233","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3389\/fphar.2020.01002","article-title":"O-1602, an agonist of atypical cannabinoid receptors GPR55, reverses the symptoms of depression and detrusor overactivity in rats subjected to corticosterone treatment","volume":"11","author":"Wr\u00f3bel","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1234","doi-asserted-by":"crossref","first-page":"172842","DOI":"10.1016\/j.pbb.2019.172842","article-title":"Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways","volume":"189","author":"Wr\u00f3bel","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000523_bib1235","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/molecules25061384","article-title":"A novel alternative in the treatment of detrusor overactivity? In vivo activity of O-1602, the newly synthesized agonist of GPR55 and GPR18 cannabinoid receptors","volume":"25","author":"Wr\u00f3bel","year":"2020","journal-title":"Molecules"},{"key":"10.1124\/pharmrev.121.000523_bib1236","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2007.02.046","article-title":"Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse","volume":"565","author":"Wuest","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1237","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00345-011-0655-6","article-title":"The muscarinic receptor antagonist propiverine exhibits \u03b1(1)-adrenoceptor antagonism in human prostate and porcine trigonum","volume":"29","author":"Wuest","year":"2011","journal-title":"World J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1238","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/ijcp.12425","article-title":"Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials","volume":"68","author":"Wyndaele","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib1239","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.sc.3101318","article-title":"Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity","volume":"40","author":"Wyndaele","year":"2002","journal-title":"Spinal Cord"},{"key":"10.1124\/pharmrev.121.000523_bib1240","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.juro.2012.08.222","article-title":"Roles of polyuria and hyperglycemia in bladder dysfunction in diabetes","volume":"189","author":"Xiao","year":"2013","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1241","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1124\/jpet.113.210708","article-title":"BK channel-mediated relaxation of urinary bladder smooth muscle: a novel paradigm for phosphodiesterase type 4 regulation of bladder function","volume":"349","author":"Xin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1242","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1243","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.110.172288","article-title":"Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder","volume":"336","author":"Yamada","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1244","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.13868","article-title":"Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study)","volume":"26","author":"Yamaguchi","year":"2019","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1245","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bju.13068","article-title":"Safety and efficacy of mirabegron as \u201cadd-on\u201d therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)","volume":"116","author":"Yamaguchi","year":"2015","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1246","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50\u2009mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1247","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-410X.2007.07031.x","article-title":"Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder","volume":"100","author":"Yamaguchi","year":"2007","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1248","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/iju.12372","article-title":"Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial","volume":"21","author":"Yamaguchi","year":"2014","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1249","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1097\/01.ju.0000085596.11247.78","article-title":"The functional role of \u03b2-adrenoceptor subtypes in mediating relaxation of pig urethral smooth muscle","volume":"170","author":"Yamanishi","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1250","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/nau.24285","article-title":"A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)","volume":"39","author":"Yamanishi","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1251","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0022-5347(17)35184-4","article-title":"Effects of beta 2-stimulants on contractility and fatigue of canine urethral sphincter","volume":"151","author":"Yamanishi","year":"1994","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1252","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/iju.IJU_306_18","article-title":"Female underactive bladder\u2014current status and management","volume":"35","author":"Yamany","year":"2019","journal-title":"Indian J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1253","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1113\/jphysiol.2010.197319","article-title":"Properties of urethral rhabdosphincter motoneurons and their regulation by noradrenaline","volume":"588","author":"Yashiro","year":"2010","journal-title":"J Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1254","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF00571623","article-title":"A double-blind clinical trial of a \u03b22-adrenergic agonist in stress incontinence","volume":"4","author":"Yasuda","year":"1993","journal-title":"Int Urogynecol J"},{"key":"10.1124\/pharmrev.121.000523_bib1255","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell","year":"2018","journal-title":"BMJ Open"},{"key":"10.1124\/pharmrev.121.000523_bib1256","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/iju.14176","article-title":"OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis)","volume":"27","author":"Yokoyama","year":"2020","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1257","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000345055","article-title":"Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study","volume":"90","author":"Yokoyama","year":"2013","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.121.000523_bib1258","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1742-1241.2011.02838.x","article-title":"Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study","volume":"66","author":"Yoo","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib1259","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bju.14387","article-title":"Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder","volume":"122","author":"Yoo","year":"2018","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1260","first-page":"294","article-title":"Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia","volume":"60","author":"Yoong","year":"2005","journal-title":"Med J Malaysia"},{"key":"10.1124\/pharmrev.121.000523_bib1261","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0531-5565(00)00175-3","article-title":"Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles","volume":"36","author":"Yoshida","year":"2001","journal-title":"Exp Gerontol"},{"key":"10.1124\/pharmrev.121.000523_bib1262","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/iju.13596","article-title":"Long-term safety and efficacy of the novel \u03b23 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study","volume":"25","author":"Yoshida","year":"2018","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1263","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1254\/jphs.FM0070115","article-title":"Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance","volume":"106","author":"Yoshida","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000523_bib1264","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective b3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/iju.13877","article-title":"Efficacy of novel \u03b23 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study","volume":"26","author":"Yoshida","year":"2019","journal-title":"Int J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1266","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bju.15020","article-title":"Efficacy of vibegron, a novel \u03b23-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study","volume":"125","author":"Yoshida","year":"2020","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1267","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/bph.12403","article-title":"Agonist pharmacology at recombinant \u03b11A- and \u03b11L-adrenoceptors and in lower urinary tract \u03b11 -adrenoceptors","volume":"170","author":"Yoshiki","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"8 Pt B","key":"10.1124\/pharmrev.121.000523_bib1268","first-page":"E397","article-title":"Inhibition of stretching-evoked ATP release from bladder mucosa by anticholinergic agents","volume":"110","author":"Young","year":"2012","journal-title":"BJU Int"},{"key":"10.1124\/pharmrev.121.000523_bib1269","doi-asserted-by":"crossref","first-page":"12231","DOI":"10.1074\/jbc.RA119.007958","article-title":"A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate","volume":"294","author":"Yu","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.121.000523_bib1270","doi-asserted-by":"crossref","first-page":"F49","DOI":"10.1152\/ajprenal.00349.2010","article-title":"Expression and distribution of transient receptor potential (TRP) channels in bladder epithelium","volume":"300","author":"Yu","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.121.000523_bib1271","doi-asserted-by":"crossref","first-page":"zqac042","DOI":"10.1093\/function\/zqac042","article-title":"Deletion of mechanosensory \u03b21-integrin from bladder smooth muscle results in voiding dysfunction and tissue remodeling","volume":"3","author":"Yu","year":"2022","journal-title":"Function"},{"key":"10.1124\/pharmrev.121.000523_bib1272","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.urology.2020.06.103","article-title":"Reversing urethral hypovascularity through testosterone and estrogen supplementation","volume":"146","author":"Yura","year":"2020","journal-title":"Urology"},{"key":"10.1124\/pharmrev.121.000523_bib1273","first-page":"333","article-title":"The use of desmopressin in the management of nocturnal enuresis in patients with spinal cord injury","volume":"43","author":"Zahariou","year":"2007","journal-title":"Eura Medicophys"},{"key":"10.1124\/pharmrev.121.000523_bib1274","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12035-018-1131-8","article-title":"The role of the periaqueductal gray matter in lower urinary tract function","volume":"56","author":"Zare","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.1124\/pharmrev.121.000523_bib1275","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.lfs.2007.01.046","article-title":"Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium","volume":"80","author":"Zarghooni","year":"2007","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000523_bib1276","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2009.04.045","article-title":"Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study","volume":"57","author":"Z\u00e1t\u2019ura","year":"2010","journal-title":"Eur Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1277","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/nau.21219","article-title":"Bladder mechanoreceptor changes after artificial bladder outlet obstruction in the anesthetized rat","volume":"31","author":"Zeng","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1278","first-page":"875","article-title":"Expression and diagnosis of transient receptor potential vanilloid1 in urothelium of patients with overactive bladder","volume":"29","author":"Zhang","year":"2015","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1124\/pharmrev.121.000523_bib1279","doi-asserted-by":"crossref","first-page":"35672","DOI":"10.1038\/srep35672","article-title":"Specific inhibition of ICAM-1 effectively reduces bladder inflammation in a rat model of severe non-bacterial cystitis","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.121.000523_bib1280","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.112.196113","article-title":"Activation of neurokinin-1 receptors increases the excitability of guinea pig dorsal root ganglion cells","volume":"343","author":"Zhang","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1281","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.115.226845","article-title":"Role of \u00b5, \u03ba, and \u03b4 opioid receptors in tibial inhibition of bladder overactivity in cats","volume":"355","author":"Zhang","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000523_bib1282","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejphar.2016.07.029","article-title":"Effects of thienorphine on the contraction of isolated ureter and bladder of guinea pigs","volume":"789","author":"Zhou","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000523_bib1283","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.121.000523_bib1284","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1368-5031.2005.00770.x","article-title":"Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB","volume":"60","author":"Zinner","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1124\/pharmrev.121.000523_bib1285","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/nau.21000","article-title":"Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms","volume":"30","author":"Zinner","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/pharmrev.121.000523_bib1286","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1532-5415.2002.50203.x","article-title":"Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients","volume":"50","author":"Zinner","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1124\/pharmrev.121.000523_bib1287","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.GME.0000148645.93603.62","article-title":"Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: a randomized clinical trial","volume":"12","author":"Zullo","year":"2005","journal-title":"Menopause"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724007749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724007749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.121.000523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T04:42:15Z","timestamp":1739853735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724007749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":1286,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0031699724007749"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.121.000523","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.121.000523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}